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ZUSAMMENFASSUNG I 
 
Zusammenfassung 
Dendritische Zellen (dendritic cells, DC) sind professionelle 
antigenpräsentierende Zellen mit einer Schlüsselrolle bei antigenspezifischen 
Immunreaktionen und der Erhaltung von T Zelltoleranz. DC entwickeln sich 
aus hämatopoetischen Stammzellen des Knochenmarks und heute bietet sich 
ein zunehmend präziseres Bild ihrer Entwicklung über verschiedene 
hämatopoetische Vorläuferzellstadien. So wurde kürzlich eine gemeinsame 
DC Vorläuferzelle (common dendritic cell progenitor, CDP) für „klassische“ DC 
(conventional DC, cDC) und plasmazellähnliche DC (plasmacytoid DC, pDC) 
beschrieben. Die molekularen Mechanismen, die die Entwicklung von CDP 
aus hämatopoetischen Stammzellen und die CDP Spezifizierung in die DC 
Subtypen cDC und pDC bestimmen, blieben jedoch weiterhin unklar. Dies 
liegt zum Teil am Fehlen genetischer Systeme und/oder Zellkulturmodellen, 
die es erlauben würden, die Auswirkung einzelner Faktoren (wie z. B. von 
Transkriptionsfaktoren und Zytokinen) auf die verschiedenen Stadien der DC 
Entwicklung zu untersuchen. In der hier vorliegenden Doktorarbeit habe ich 
ein Kultursystem etabliert, das die Entwicklung von CDP aus 
hämatopoetischen Stammzellen unter definierten Bedingungen in vitro 
nachvollzieht. Desweiteren habe ich die molekularen Mechanismen analysiert, 
die zur Spezifizierung von CDP in cDC und pDC führen. 
Die in vitro amplifizierten CDP können Funktion, Oberflächenmarker- und 
Genexpressionsprofile der in vivo CDP nachvollziehen und liefern damit ein 
wertvolles Modellsystem zur Erforschung der molekularen Mechanismen der 
DC Entwicklung. Genomweite Genexpressionsanalysen zeigten, dass CDP 
ein für DC prädestiniertes Transkriptionsprofil besitzen. Dies beinhaltet die 
Expression von DC spezifischen Zelloberflächenrezeptoren und Transkrip-
tionsfakoren. Übereinstimmend mit der Fähigkeit, sich in cDC und pDC zu 
entwickeln, exprimieren CDP (i) Gene, die für alle DC Subtypen gleich sind 
und (ii) auch Gene, die für die DC Subtypen spezifisch sind. Bei der 
Differenzierung von CDP in cDC und pDC, werden stamm- und/oder 
vorläuferzellspezifische Gene und Gene der Zellproliferation herunterreguliert 
und dies geht einher mit dem Verlust der Fähigkeit zur Selbsterneuerung und 
dem multiplen Differenzierungspotential. 
In diese Arbeit habe ich dann die Bedeutung von transforming growth factor-
β1 (TGF-β1) für die CDP Differenzierung und die DC Subtypspezifizierung 
untersucht. TGF-β1 ist ein multifunktionelles Zytokin mit einer fundamentalen 
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Bedeutung für DC. In genomweiten Genexpressionsanalysen konnte ich 
zeigen, dass das Transkriptionsprofil von CDP durch TGF-β1 innerhalb von 24 
Stunden in Richtung eines DC-spezifischen Profils verschoben wird. Damit 
beschleunigt TGF-β1 die Differenzierung von CDP in DC. Dies geht einher mit 
(i) der Hochregulierung von Genen mit einer Bedeutung bei der DC 
Differenzierung und/oder Funktion und (ii) der Herunterregulierung von 
proliferationsassoziierten Genen. Auch wurde beobachtet, dass TGF-β1 die 
Subtypspezifizierung in Richtung cDC beeinflusst. Nach Behandlung mit TGF-
β1 erwerben CDP ein cDC-spezifisches Transkriptionsfaktorrepertoire, z. B. 
die Induktion des Transkriptionsfaktors interferon regulatory factor-4 (IRF-4) 
und mehrere Mitglieder der nuclear factor-κB (NF-κB) Transkriptionsfaktoren, 
die dann die cDC Differenzierung einleiten. Gleichzeitig induziert TGF-β1 
Transkriptionsfaktoren, wie z. B. inhibitor of DNA binding/differentiation 2 (Id2) 
und interferon regulatory factor-1 (IRF-1), die die pDC Differenzierung 
blockieren. 
Zusammenfassend, diese Arbeit beschreibt ein in vitro Zellkultursystem zur 
Bestimmung der aufeinanderfolgenden molekularen Schritte bei der 
Entwicklung von multipotenten Vorläuferzellen in CDP und deren weitere 
Differenzierung in die DC Subtypen cDC und pDC. Desweiteren wurde hier 
erstmalig TGF-β1 als bestimmender Faktor in der DC Subtypspezifizierung 
von CDP in Richtung cDC identifiziert. 
 
SUMMARY III 
 
Summary 
Dendritic cells (DC) are bone marrow-derived antigen presenting cells that are 
crucial for inducing adaptive immune responses and maintaining T cell 
tolerance. An increasingly precise picture of DC development from bone 
marrow progenitors is emerging, including the discovery of a DC lineage 
restricted common DC progenitor (CDP). The molecular mechanisms 
determining DC commitment of CDP and their further specification into DC 
subsets remained, however, less clear. This is partly due to the lack of genetic 
tools and/or culture model systems that would allow the developmental stage-
specific analysis of the impact of single factors, like transcription factors and 
cytokines, on DC development. In this study, I have developed a culture 
system that reproduces CDP in vitro and addressed the molecular 
mechanisms behind DC commitment of CDP from multipotent progenitors 
(MPP). 
The in vitro amplified CDP recapitulate the function, surface marker and gene 
expression profile of in vivo CDP, therefore providing a valuable model system 
for studying DC development. Gene expression analysis by DNA microarrays 
showed that CDP exhibit a DC-primed transcription profile that includes the 
upregulation of DC-poietin receptors and DC specific transcription profiles 
upon differentiation from MPP. Consistent with their capacity to generate both 
conventional DC (cDC) and plasmacytoid DC (pDC), CDP express pan-DC 
genes as well as genes specific for either DC subset. Concomitantly with 
lineage specification, hematopoietic cells cease proliferating and undergo cell 
cycle arrest. In line with the loss of self-renewal capacity and multilineage 
potential, CDP differentiation from MPP is accompanied by downregulation of 
stem/progenitor cell associated gene expression. 
In addition, this thesis addressed the impact of transforming growth factor-β1 
(TGF-β1) on DC differentiation. DNA microarray analysis showed that TGF-β1 
pushed the CDP transcription profile towards DC within 24 h, indicating that 
TGF-β1 accelerates DC differentiation from CDP. This was accompanied with 
upregulation of genes involved in DC differentiation and/or function and 
downregulation of proliferation associated genes. Most importantly, TGF-β1 
directed DC subset specification towards cDC. TGF-β1 treated CDP acquired 
a cDC affiliated transcription factor repertoire, with the induction of cDC 
differentiation instructing transcriptional regulators, including interferon 
regulatory factor-4 (IRF-4) and several members of the nuclear factor-κB (NF-
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κB) family. Concurrently, TGF-β1 induced transcription factors that inhibit pDC 
differentiation, such as inhibitor of DNA binding/differentiation 2 (Id2) and 
interferon regulatory factor-1 (IRF-1). 
Taken together, this study describes an in vitro system for studying the 
consecutive development of MPP towards CDP and their further differentiation 
into DC subsets. Employing the culture system, the molecular mechanisms 
instructing DC commitment and subset specification were analysed. For the 
first time, TGF-β1 was identified as a determining factor that regulates DC 
subset specification and directs DC differentiation towards cDC. 
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1 Introduction 
1.1 The Immune System 
The body needs to constantly defend itself against pathogenic viruses, 
bacteria and parasites that it gets exposed to. The evolved defence 
mechanisms can be divided into innate and adaptive arms of immunity. Innate 
immunity represents the first line of defence and consists of physical barriers 
such as skin and mucosa, white blood cells such as granulocytes and 
macrophages and the microbicidal products of these cells. Innate immunity 
acts non-specifically to rapidly eliminate pathogens and so controls the 
majority of infections (Medzhitov and Janeway, 2000; Janeway, 2001; 
Janeway and Medzhitov, 2002; Chaplin, 2010). Frequently however, innate 
immunity alone is insufficient to clear the evading pathogens and adaptive 
immunity is required. Adaptive immunity depends upon the function of another 
group of white blood cells, B and T lymphocytes. Lymphocytes act antigen-
specifically and by rearranging their antigen receptor genes they can express 
millions of different variants of antigen receptors on their surface (Cooper and 
Alder, 2006; Bonilla and Oettgen, 2010). Upon encountering an antigen, the 
antigen-specific lymphocyte proliferates and differentiates to produce a clone 
of effector cells. The effector cells either produce neutralising antibodies (B 
cells), help in the antibody generation process (CD4+ T helper cells) or directly 
kill infected cells (cytotoxic CD8+ T cells) (Chaplin, 2010; Bonilla and Oettgen, 
2010). Some of the antigen-specific lymphocytes are retained as so called 
memory cells after the immune response to form immunological memory. In 
case of a repeated contact with the same antigen, the memory cells allow a 
faster and more effective immune response (Ahmed and Gray, 1996). 
 
1.2 Antigen Presenting Cells 
Naïve B and T lymphocytes recirculate constantly through peripheral lymphoid 
organs –lymph nodes, spleen and mucosal lymphoid tissues– and remain 
dormant until activated via their antigen receptors, B cell receptor (BCR) and T 
cell receptor (TCR), respectively (Bonilla and Oettgen, 2010). As pathogens 
often utilise various routes to invade peripheral tissues, the chance of an 
antigen-specific lymphocyte to encounter its specific antigen is highly unlikely. 
Hence, the immense task of surveying all tissues and organs for infections is 
left for the antigen-presenting cells (APC), which include dendritic cells (DC) 
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and macrophages (Steinman, 2007; Steinman and Banchereau, 2007). The 
circulating naïve lymphocytes and the antigen delivered by APC then 
encounter each other in peripheral lymphoid organs, where the APC displays 
the antigen. A second signal, so called “danger signal”, is required to induce 
clonal expansion of antigen-specific lymphocytes (Matzinger, 1998). This 
signal is delivered by APC for T cells and by CD4+ T helper cells for B cells. 
 
1.3 Dendritic Cell Biology 
DC are cells of the innate immunity that are specialised in ingesting antigens 
and presenting them to naïve T cells in lymph nodes. They are the most 
potent T cell activators, thus, very important in linking innate and adaptive 
immunity and inducing adaptive immune responses. In order to fulfil their 
function in immune surveillance, DC form vast networks in tissues, especially 
at environmental contact sites such as skin, lung and intestine and at filtering 
sites such as liver and spleen (Steinman, 2007; Steinman and Banchereau, 
2007; Merad and Manz, 2009). 
The capability for phagocytosis, macropinocytosis and the expression of 
receptors mediating adsorptive endocytosis (e.g. C-type lectin receptors and 
Fcγ and Fcε receptors) make DC particularly effective in antigen uptake 
(Geijtenbeek and Gringhuis, 2009; Steinman, 2007; Banchereau and 
Steinman, 1998). Extracellular antigens (e.g. bacterial components) are 
directed to the lysosomal route, where they are processed and loaded on 
major histocompatibility complex (MHC) class II molecules for antigen 
presentation on the cell surface (Gannage and Munz, 2009). Intracellular 
antigens (e.g. viral proteins) are processed in the cytosol and bind to MHC 
class I molecules for presentation (Hansen and Bouvier, 2009). Antigens 
presented on MHC I molecules are recognised by CD8+ cytotoxic T cells, 
whereas antigen presentation on MHC II activates CD4+ helper T cells. The 
cytokine and surface molecule repertoire of the antigen-presenting DC can 
polarise the naïve T cells into T helper (Th) 1, Th2, Th17 or regulatory T cells 
(Treg), which all have different functions in terms of immunogenicity (Blanco et 
al., 2008). 
 
DC are not only important in inducing immune responses, but they also play a 
crucial role in maintaining (central and peripheral T cell) tolerance (Steinman, 
2007; Steinman and Banchereau, 2007; Blanco et al., 2008). Since DC take 
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up both “self” and “non-self” antigens it is essential to discriminate between 
them. Therefore, DC, as other cells of the innate immunity, express a variety 
of receptors that recognise pathogen-associated molecular patterns (PAMP). 
These pattern recognition receptors include Toll like receptors (TLR) and C-
type lectin receptors (CLR). TLR recognise e.g. cell-wall components of 
bacteria, fungi and protozoa or viral and bacterial nucleic acid structures, while 
patter recognition associated CLR bind to carbohydrate structures of 
pathogens (Akira et al., 2001; Geijtenbeek and Gringhuis, 2009). Recognition 
of a PAMP and inflammatory cytokines induce DC activation and lead to up-
regulation of co-stimulatory molecules on DC surface (Granucci et al., 2004; 
Foti et al., 2004; Blanco et al., 2008). The co-stimulatory molecules on DC 
surface and DC-secreted cytokines are required to deliver the “danger signal” 
for T cell activation upon antigen presentation, as discussed above. If DC 
capture self-antigens in steady state, they do not get activated. Self-antigen 
presentation by non-activated DC leads to generation of peripheral tolerance 
by silencing T cells that react to these antigens (Steinman and Nussenzweig, 
2002; Lutz and Kurts, 2009). 
 
1.4 Dendritic Cell Subsets 
DC are divided into several subsets according to their localisation, phenotype 
and function. The main DC subsets are non-lymphoid tissue migratory DC that 
are spread throughout peripheral organs and conventional DC (cDC) and 
plasmacytoid DC (pDC) found in lymphoid tissue such as spleen and lymph 
nodes (Shortman and Naik, 2007; Merad and Manz, 2009). 
 
1.4.1 Tissue DC 
Tissue DC comprise interstitial DC (DC of e.g. dermis, mucosa and lung) and 
epidermal Langerhans cells (LC) and can be regarded as the classical antigen 
presenting DC. Accordingly, they have a typical DC phenotype with long 
extensions/protrusions enabling them to survey a large area of their 
environment. They are specialised in capturing particles, processing them and 
presenting antigens for naïve T cells. Tissue DC are also called migratory DC, 
since upon antigen capture and activation, and even in steady state, they 
constantly migrate from peripheral tissues via the lymphatics to the draining 
lymph nodes (Huang et al., 2000; Hemmi et al., 2001; Henri et al., 2001; 
Scheinecker et al., 2002; Jakubzick et al., 2008). 
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Different tissue DC have been studied in more detail in recent years. 
Especially skin DC have been thoroughly characterised and are now divided 
into epidermal LC and CD103+Langerin+CD11blo DC and CD11c+CD11b+ DC 
of the dermis (Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007). 
Similarly, DC in other non-lymphoid tissues can be divided into CD103+ DC 
and CD11b+ DC (Ginhoux et al., 2009; Bogunovic et al., 2009; Varol et al., 
2009). The different tissue DC subsets not only differ in their phenotype, but 
also in their origin and molecular requirements during development (see 
Chapter 1.6). 
 
1.4.2 Lymphoid Organ Resident cDC 
cDC are resident DC of lymphoid organs and do not migrate through the 
lymphatic vessels. They function as APC and present antigens in their 
resident lymphoid organs. They can be further divided into CD8α+ and CD8α- 
DC (Vremec et al., 1992; Vremec et al., 2000; Shortman and Liu, 2002). The 
different cDC subsets have specialised functions: CD8α+ DC are more potent 
at cross-presenting soluble and cell-associated antigens on MHC class I 
molecules to CD8+ T cells (Heath et al., 2004; Belz et al., 2005) and 
preferentially prime CD8+ T cells. CD8α- DC instead are more efficient in 
processing and presenting antigen on MHC class II to CD4+ T cells (Dudziak 
et al., 2007). Accordingly, CD8α+ and CD8α- cDC differ in their cytokine 
production to differentially regulate immune responses (Hochrein et al., 2001; 
Proietto et al., 2004). 
 
1.4.3 Circulatory pDC 
pDC have a plasma cell-like phenotype in steady state and are found in blood 
and in many organs like thymus, bone marrow and the T cell areas of 
lymphoid organs (Nakano et al., 2001; Asselin-Paturel et al., 2003; O'Keeffe et 
al., 2003; Okada et al., 2003). pDC are specialised in recognising viral 
infections and express the appropriate repertoire of pattern recognition 
molecules, such as TLR7 and TLR9 that recognise bacterial and viral nucleic 
acids (Colonna et al., 2004). Upon activation by respective TLR ligands pDC 
produce vast amounts of type I interferons (IFN) and acquire a DC-like 
phenotype. Activated pDC are able to prime T cells against viral antigens, 
although they are poor T cell activators compared to tissue DC and cDC 
(Colonna et al., 2004; Fuchsberger et al., 2005; Villadangos and Young, 
INTRODUCTION 5 
 
2008). 
 
1.4.4 Inflammatory DC 
Inflammatory DC are a specific DC subset that develop from monocytic 
precursors only under inflammatory conditions and that have no steady state 
counterpart. Inflammatory DC include the so called TipDC that, at least after 
microbial infection, produce tumour necrosis factor  α (TNFα), inducible nitric 
oxide synthase (iNOS) and oxygen radicals (Serbina et al., 2003a; Serbina et 
al., 2003b). The function of inflammatory DC is still rather unclear. Some 
studies have shown them to be able to perform antigen presentation to T cells, 
while others only observed direct microbial killing by monocyte-derived DC 
(Geissmann et al., 2008; Auffray et al., 2009b). 
 
1.4.5 Human DC 
The mouse DC subsets, described above, roughly have their human 
counterparts, although the human DC subsets are less well characterised due 
to lack of readily available sources except for peripheral blood. Tissue DC, 
such as LC, are found in human and LC were actually the first DC ever 
described although their role in immunity became evident only much later 
(Romani et al., 2003). Human pDC that produce type I interferon upon viral 
infections have also been described as circulating cells in peripheral blood but 
also present in lymphoid tissues (Colonna et al., 2004). Lymphoid organ 
resident DC subsets in human have been more difficult to compare to the 
mouse ones. First, they do not express the CD8α surface marker used to 
characterise mouse cDC, and second it is more difficult to access material in 
human (Shortman and Liu, 2002). However, human DC subsets found in e.g. 
thymus show similar heterogeneity in surface marker expression as mouse 
cDC and the counterparts for mouse CD8α- cDC and CD8α+ cDC in human 
with and without “myeloid” marker expression, respectively, have been 
described (Shortman and Liu, 2002). 
 
1.5 Hematopoiesis 
All adult blood cells derive from hematopoietic stem cells (HSC) residing in the 
bone marrow. By undergoing cell division and passing through branch points, 
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HSC become developmentally restricted in a stepwise fashion. These 
consecutive events of restriction and commitment are finely regulated by 
transcription factors (Orkin, 2000; Orkin and Zon, 2008). 
Traditionally, hematopoiesis is depicted as a hierarchical, binary cell fate tree, 
where blood cells are divided into lymphoid and myeloid/erythroid lineages 
(Fig. 1.1) (Morrison et al., 1995b; Orkin, 2000; Reya et al., 2001). In such 
classical model, the first commitment step of pluripotent HSC results in a strict 
separation into common lymphoid progenitors (CLP) and common myeloid 
progenitors (CMP). Lymphoid T, B and natural killer (NK) cells develop from 
CLP that lack myeloid potential (Kondo et al., 1997), whereas CMP further 
divide into megakaryocyte/erythrocyte progenitors (MEP) and granulocyte/ 
macrophage progenitors (GMP), generating the cells of the myeloid lineage 
(Akashi et al., 2000). However, the traditional model of hematopoiesis has 
been recently challenged. First (i), recent findings implicate the existence of 
multipotent progenitors (MPP) with granulocyte-macrophage and lymphoid 
potential, but little or no megakaryocyte-erythroid (MkE) potential (Adolfsson et 
al., 2005; Lai and Kondo, 2006). Second (ii), cells of lymphoid lineage have 
been shown to maintain myeloid potential even as late as pro-T and pro-B 
cells. Also, B cells deficient for a crucial transcription factor for their 
development, PAX5, were shown to loose their lineage commitment and 
regain the potential to give rise to T cells and myeloid cells (Nutt et al., 1999; 
Rolink et al., 1999). These pro-B cells from PAX5-/- mice are multipotent, and 
similar cells have been found in the bone marrow of wildtype mice (Balciunaite 
et al., 2005a). Third (iii), thymic lymphoid progenitors have been shown to 
have both lymphoid and myeloid potential (Balciunaite et al., 2005b; Wada et 
al., 2008; Bell and Bhandoola, 2008). And fourth (iv), in vivo transfer 
experiments have shown that CMP consistently give rise to a minor, but 
persistent population of B cells in irradiated recipients (Akashi et al., 2000; 
D'Amico and Wu, 2003). Therefore, alternative models for hematopoiesis have 
been proposed. These models include the myeloid-based model from 
Kawamoto & Katsura (Kawamoto and Katsura, 2009) and the pairwise 
relationships model from Cederig et al. (Ceredig et al., 2009) that try to 
account for the developmental plasticity observed in hematopoiesis. 
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Figure 1.1. Hierarchy of hematopoietic cells. 
Scheme of hematopoiesis shows the division into myeloid and lymphoid lineages and the 
differentiation potential of various progenitors cells. Reproduced from Larsson and Karlsson, 
2005. 
 
1.6 Dendritic Cell Development 
1.6.1 DC Development in Steady State 
DC development shows remarkable plasticity and DC are difficult to position in 
traditional lineage maps. DC have been shown to develop from both lymphoid 
and myeloid compartments via FMS-like tyrosine kinase 3 (Flt3) expressing 
progenitors (Manz et al., 2001; D'Amico and Wu, 2003; Karsunky et al., 2003). 
Indeed, the expression of Flt3 is an essential requirement for DC development 
(McKenna et al., 2000; Brawand et al., 2002; Onai et al., 2007a; Waskow et 
al., 2008; Kingston et al., 2009) and DC differentiation can be rescued by 
enforced Flt3 expression from Flt3- cells (Onai et al., 2006). Reflecting the 
plasticity of DC development, it was long unclear whether the DC lineage has 
a common, DC-restricted progenitor. Recently, clonogenic DC progenitors 
have been described: a c-kit+M-CSFR+CX3CR1+ macrophage/DC progenitor 
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(MDP) (Fogg et al., 2006; Auffray et al., 2009a) and a Flt3+c-kitintM-CSFR+ 
common DC progenitor (CDP) (Fig. 1.2) (Onai et al., 2007b; Naik et al., 2007). 
While MDP give rise to both macrophages and DC, CDP are DC-restricted 
and do not generate other cell types (Fig. 1.2). Indeed, MDP have been shown 
to be more heterogeneous and to contain CDP (Waskow et al., 2008; Auffray 
et al., 2009a). 
As DC are a heterogeneous group of cells, the developmental origin of each 
subset has still to be addressed. The original publications describing CDP 
demonstrated that CDP give rise the lymphoid tissue DC subsets, namely 
CD8α+ cDC, CD8α- cDC and pDC. More recent studies have addressed the 
origin of non-lymphoid tissue DC in more detail and the data indicate that also 
CD103+ DC and CD11b+ DC originate from CDP in a Flt3-dependent manner 
(Fig. 1.2 and Fig. 1.3) (Ginhoux et al., 2009; Varol et al., 2009; Bogunovic et 
al., 2009). Only a special subset of CD103-CD11b+CX3CR1+ 
mucosal/intestinal lamina propria DC derive macrophage colony-stimulating 
factor (M-CSF)-depently from monocytes under steady state conditions (Fig. 
1.2 and Fig. 1.3) (Varol et al., 2009; Bogunovic et al., 2009). 
 
1.6.2 DC Development in Inflammation 
DC development differs under steady state and inflammatory conditions. In 
steady state, DC develop from CDP into several subsets as described above. 
Under inflammatory conditions, however, DC can develop from monocytes (as 
described in Chapter 1.4.4). Monocyte derived DC are called inflammatory DC 
and, at least following microbial infection, produce TNFα, iNOS and 
upregulate CD11c, MHC class II and the co-stimulatory molecules CD80 and 
CD86 (Fig. 1.2) (Serbina et al., 2003a; Serbina et al., 2003b). Importantly, 
monocytes do not serve as DC progenitors under steady state conditions 
(Fogg et al., 2006; Naik et al., 2006; Varol et al., 2007; Ginhoux et al., 2009; 
Varol et al., 2009; Bogunovic et al., 2009), except for a subset of CD103-
CD11b+CX3CR1+ intestinal lamina propria DC (Fig. 1.2) (Varol et al., 2009; 
Bogunovic et al., 2009). Monocyte derived DC clearly differ from the classical 
steady state DC in their function and cytokine dependency during 
development. Monocyte differentiation into DC depends on M-CSF and 
granulocyte/macrophage colony-stimulating factor (GM-CSF), whereas DC 
development from CDP is dependent on Flt3 ligand (Flt3L) (Fig. 1.3) (Sallusto 
and Lanzavecchia, 1994; Naik et al., 2006; Waskow et al., 2008; Ginhoux et 
al., 2009; Varol et al., 2009; Bogunovic et al., 2009). 
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Monocyte derived DC have been described both in T cell priming and killing 
bacteria during inflammation in vivo (Narni-Mancinelli et al., 2007; Serbina et 
al., 2003b). In steady state, however, the monocyte derived lamina propria DC 
in intestine do not function in immunosurveillance and maintenance of T cell 
tolerance to harmless antigens. They are also not involved in the first, acute 
wave of antigen presentation in draining lymph nodes (Varol et al., 2009). 
 
 
Figure 1.2. DC development from bone marrow derived progenitors in steady state and 
inflammation. 
In the bone marrow, hematopoietic stem cells (HSC) produce myeloid (MP) and lymphoid (LP) 
committed progenitors. MP give rise to monocyte, macrophage and DC progenitors (MDP), 
which in turn generate monocytes, some macrophage populations and common DC 
progenitors (CDP). CDP give rise to pre-conventional DC (pre-cDC) and plasmacytoid DC 
(pDC). Pre-cDC circulate in blood and enter lymphoid tissue, where they give rise to CD8α+ 
and CD8α- cDC, and non-lymphoid tissues, where they may give rise to CD103+ lamina 
propria DC (lpDC). In steady state, Ly-6C- monocytes may contribute to alveolar 
macrophages (Mφ) and Ly-6C+ monocytes can become CX3CR1+ lpDC in non-lymphoid 
tissues. During inflammation, Ly-6C+ monocytes give rise to monocyte-derived DC, like TNFα 
and iNOS producing TipDC, and inflammatory macrophages. They can also contribute to 
microglia and Langerhans cells (LC) in selected experimental conditions, like in inflammation 
(dashed arrow). It is unclear whether LP contribute substantially to pDC and cDC (dashed 
arrow). Reproduced from Geissmann et al., 2010. 
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Figure 1.3. Cytokine dependency of DC development in steady state and inflammation. 
(A) In steady state, all lymphoid tissue DC and some non-lymphoid tissue DC develop from 
CDP. DC development from CDP is dependent on Flt3 signalling. (B) Monocytes can give rise 
to lymphoid tissue DC during inflammation and to certain non-lymphoid tissue DC with and 
without inflammation. Lymphoid tissue DC development from monocytes depends on GM-
CSF whereas monocyte derived non-lymphoid tissue DC development is M-CSF dependent. 
 
1.6.3 LC Development 
LC development forms an exception in DC development. All the other DC are 
relatively short-lived in the periphery and constantly need to be replenished by 
hematopoietic progenitor cells from the bone marrow. On the contrary, LC 
have been shown to develop from progenitors that seed the skin already 
during embryonic development and that are able to maintain the epidermal LC 
network for the life-time (Merad et al., 2002; Chorro et al., 2009). Only under 
inflammatory conditions, e.g. after UV light irradiation, LC are replaced by 
circulating monocytes (Fig. 1.2) (Merad et al., 2002; Ginhoux et al., 2006). LC 
development is regulated by transforming growth factor β1 (TGF-β1) and M-
CSF as mice deficient for TGF-β1 or M-CSF receptor lack LC (Borkowski et 
al., 1996; Ginhoux et al., 2006) and LC frequencies are reduced in newborn 
M-CSF deficient (CSF-1op/op) mice (Dai et al., 2002). 
 
1.7 Molecular Mechanisms in DC Development 
The molecular mechanisms regulating DC development are under vivid 
investigation. The mechanisms can be divided into external and internal cues. 
External cues include cytokines and growth factors and their receptors, 
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whereas internal, cell intrinsic cues include transcription factors (Tables 1.1 
and 1.2, respectively). The mechanisms intertwine to finely regulate DC 
development: context-dependent expression of growth factors and cytokines 
regulates the expression of transcription factors. Transcription factors, in turn, 
can regulate the expression of growth factor and cytokine receptors (Carotta 
et al., 2010). The current understanding of DC development is mainly based 
on studies of genetically modified mice and knockout models that lack 
cytokines, their receptors or transcription factors (reviewed in Zenke and 
Hieronymus, 2006; Wu and Liu, 2007; Merad and Manz, 2009). 
 
1.7.1 External Cues in DC Development 
Flt3L is the ligand for the FMS-like tyrosine kinase 3. It is the major cytokine 
for DC development in steady state in vivo: Flt3L is a potent inducer of both 
cDC and pDC development in human and mice (Maraskovsky et al., 1996; 
Pulendran et al., 2000; Bjorck, 2001). Accordingly, Flt3 and Flt3L deficient 
mice have a severe reduction in DC numbers in several lymphoid organs and 
non-lymphoid tissues (McKenna et al., 2000; Brawand et al., 2002; Waskow et 
al., 2008; Kingston et al., 2009). Bone marrow cultures with Flt3L give rise to 
CD8α+ cDC, CD11bhi cDC and pDC (Brasel et al., 2000; Brawand et al., 
2002; Gilliet et al., 2002) . According to the current view, the Flt3L generated 
DC are considered as in vitro equivalents of the lymphoid tissue, steady state 
DC as for example found in spleen (Naik et al., 2005). 
M-CSF, macrophage colony-stimulating factor, is a monocyte/macrophage 
differentiation inducing cytokine. It was described as a DC-poietin only 
recently (Fancke et al., 2008), giving rise to pDC and CD11bhi cDC but not 
CD8α+ cDC in bone marrow cultures. Its potential as a DC-poietin, however, is 
significantly lower than that of Flt3L (Fancke et al., 2008). Interestingly, 
administration of M-CSF induces both cDC and pDC generation in vivo 
(Fancke et al., 2008). M-CSF deficient (CSF-1op/op) mice have reduced 
numbers of splenic DC and LC (Dai et al., 2002; MacDonald et al., 2005) and 
M-CSFR deficient mice lack LC (Ginhoux et al., 2009), all demonstrating the in 
vivo relevance of M-CSF in DC development. 
GM-CSF, granulocyte/macrophage colony-stimulating factor, was the first 
cytokine used to generate DC in vitro (Inaba et al., 1992). GM-CSF is a very 
strong DC-poietin that gives rise to CD11bhi DC. However, GM-CSF levels in 
steady state mice and healthy humans are below detection levels and GM-
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CSF is, hence, unlikely to significantly contribute to in vivo DC development in 
steady state (Shortman and Naik, 2007). Accordingly, GM-CSF and GM-CSF 
receptor deficient mice have only a very mild reduction in DC numbers in 
lymphoid tissues (Vremec et al., 1997; Kingston et al., 2009). Therefore, the 
GM-CSF derived DC in vitro are thought to resemble inflammatory DC that 
have no steady state counterpart in vivo. Instead, GM-CSF appears to be to 
some extent involved in Flt3L regulated DC progenitor (MDP and CDP) 
development and homeostasis in bone marrow, as well as in the development 
of non-lymphoid tissue, dermal CD11b+ DC (Kingston et al., 2009). 
TGF-β1, transforming growth factor β1, (discussed later in Chapter 1.8). 
 
Table 1.1. Impact of cytokines and their receptors on DC development. 
Frequency of Cytokine Cytokine level 
alteration BM 
progenitors 
Splenic 
pDC 
Splenic 
cDC 
Tissue 
DC 
LC 
Flt3-/- ⇔ ⇓⇓ ⇓⇓ nd nd 
Flt3L-/- ⇓⇓ ⇓⇓ ⇓⇓ ⇓ ⇓ 
Flt3L injection ⇑ ⇑⇑ ⇑⇑ nd nd 
Flt3L expression nd ⇑⇑ ⇑⇑ ⇑⇑ nd 
Flt3L 
Flt3 sign. inhibition nd ⇓⇓ ⇓⇓ nd nd 
GM-CSFR-/- nd nd ⇔ nd nd 
GM-CSF-/- ⇓ ⇔ ⇓ ⇓ ⇓ 
GM-CSF injection nd nd ⇔ nd nd 
GM-CSF 
GM-CSF expression nd nd ⇑ nd nd 
M-CSFR-/- nd ⇔ ⇔ nd ⇓⇓ 
M-CSF-/- (op/op) nd ⇓⇓ ⇓ nd ⇓? 
M-CSF 
M-CSF injection nd ⇑ ⇑ nd nd 
TGF-β1 TGF-β1-/- nd nd nd nd ⇓⇓ 
Abbreviations: ⇔, not changed; ⇑, increased; ⇑⇑, highly increased (over 10-fold); ⇓, 
decreased; ⇓⇓, highly decreased (less than 50% of wild type); nd, not determined. Modified 
from Shortman and Naik, 2007 and Merad and Manz, 2009. 
 
1.7.2 Internal Cues in DC Development 
Some transcription factors have an essential role in regulating hematopoiesis 
and deficiencies in these factors impair the development of several DC 
subsets. Signal transducer and activator of transcription 3 (STAT3) is a central 
component of Flt3 signalling in DC and deletion of STAT3 severely impairs DC 
development (Laouar et al., 2003). PU.1, an Ets family transcription factor, is 
expressed highly in hematopoetic progenitors and cDC and in low levels in 
pDC (Nutt et al., 2005; Back et al., 2005). Mice reconstituted with PU.1 
deficient hematopoietic cells have severe hematopoietic defects and lack cDC 
(Guerriero et al., 2000; Anderson et al., 2000), and conditional PU.1 deletion 
INTRODUCTION 13 
 
in adult mice leads to drastic reduction of both cDC and pDC subsets (Carotta 
et al., 2010). The zinc finger transcriptional regulator Ikaros is required for the 
normal development of early hematopoietic progenitors (Georgopoulos et al., 
1994; Nichogiannopoulou et al., 1999) and Ikaros deficiency depending on the 
type of mutation leads to either the ablation of all DC subsets or the absence 
of specific DC subsets (Wu et al., 1997; Allman et al., 2006). 
Other transcription factors function more restricted in DC subset specification. 
The development of cDC is influenced by the interferon regulatory factors 
(IRF)-2, IRF-4 and IRF-8 (also known as ICSBP for interferon consensus 
sequence binding protein) (Ichikawa et al., 2004; Suzuki et al., 2004; Tamura 
et al., 2005; Schiavoni et al., 2002; Schiavoni et al., 2004), the helix-loop-helix 
(HLH) transcription factor Id2 (inhibitor of differentiation/DNA binding 2) 
(Hacker et al., 2003) and the nuclear factor (NF)  κB/rel family member RelB 
(Burkly et al., 1995; Weih et al., 1995; Wu et al., 1998), among others. pDC 
development on the other hand depends on the basic HLH factor E2-2 (Cisse 
et al., 2008; Nagasawa et al., 2008), the Ets-domain transcription factor Spi-B 
(Schotte et al., 2003; Schotte et al., 2004), and IRF-4 and IRF-8 (Tamura et 
al., 2005; Schiavoni et al., 2002). 
 
Table 1.2. Impact of transcription factors on DC development. 
Transcription 
factor 
pDC CD8+ cDC CD8- cDC LC 
Batf3-/- ⇔ ⇓⇓ ⇔ nd 
E2-2-/- ⇓⇓ ⇔ ⇔ nd 
Gfi-1-/- ⇓ ⇓ ⇓ ⇑ 
Id2-/- ⇑ ⇓⇓ ⇔ ⇓⇓ 
Ikaros-/-  nd ⇓⇓ ⇓⇓ nd 
Ikaros DN nd ⇓⇓ ⇓⇓ nd 
Ikaros IkL/L ⇓⇓ ⇔ ⇓ nd 
IRF-2-/- nd ⇔ ⇓⇓ ⇓ 
IRF-4-/- ⇓ ⇔ ⇓⇓ nd 
IRF-8-/- ⇓⇓ ⇓⇓ ⇔ ⇓ 
PU.1-/- nd ⇔ ⇓⇓ nd 
RelB-/- nd ⇔ ⇓⇓ ⇔ 
Runx3-/- nd ⇑ ⇓ ⇓⇓ 
STAT3-/- nd ⇓⇓ ⇓⇓ nd 
STAT5-/- ⇓⇓ ⇓⇓ ⇓⇓ nd 
Abbreviations: ⇔, not changed; ⇑, increased; ⇓, decreased; ⇓⇓, highly decreased (less than 
50% of wild type); nd, not determined. Modified from Merad and Manz, 2009. 
 
While critically adding to the understanding of DC development, it is 
worthwhile to note that the studies so far have concentrated on the phenotype 
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in mature DCs. It is yet unclear at which stage and how these factors influence 
DC development. 
 
1.8 Transforming Growth Factor-β1 
TGF-β is the founding member and prototype of a large superfamily of 
structurally related peptide growth factors. Other key members of the TGF-β 
superfamily include the activins, inhibins, bone morphogenic proteins (BMP) 
and growth and differentiation factors, such as growth and differentiation 
factor-5 (GDF5), and Müllerian inhibiting substance that all execute their effect 
via the Smad signalling pathway (Massague, 1998; Massague, 2000; Larsson 
and Karlsson, 2005). There are three isoforms of TGF-β in mammals, TGF-β1, 
2 and 3 (Heldin et al., 1997; Massague, 2000; Larsson and Karlsson, 2005), 
which are encoded by separate genes located at different chromosomes. 
Although the isoforms share 70-80% amino-acid sequence identity, bind to the 
same receptors and show very similar effects in in vitro cultures, their 
expression patterns in vivo are very distinct and the phenotypes of mice 
deficient for TGF-β1, 2 or 3 show very little overlapping. Hence, each of the 
isoform seems to have specific functions (Larsson and Karlsson, 2005). 
TGF-β1 is a pleiotropic cytokine involved in a variety of biological processes 
such as development, differentiation, apoptosis and cell survival. TGF-β1 is 
produced by many cells and is secreted as a latent form where an amino-
terminal propeptide (also called latency-associated protein, LAP) and a 
carboxy-terminal fragment constituting the mature growth factor are non-
covalently bound. The latent form of TGF-β1 is not recognised by its receptors 
and its physiological activation process is only partially understood. At least 
thrombospondin-1 and a cell adhesion molecule αvβ6 integrin have been 
implicated to have an in vivo role in this process (Heldin et al., 1997; 
Massague, 2000; Massague and Chen, 2000). 
 
1.8.1 TGF-β1 Signalling Pathway 
TGF-β1 signals via a ubiquitously expressed signalling pathway (Fig. 1.4). 
Binding of TGF-β1 to its type II receptor leads to the heteromerisation of type 
II and I (activin receptor-like kinase 5, ALK-5) TGF-β1 receptors and the 
constitutively active type II receptor activates the kinase domain of the type I 
receptor (Wrana et al. 1994). In the canonical signalling pathway the activated 
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type I receptor phosphorylates the signalling molecules Smad2/3 (receptor 
Smads, R-Smad). Phosphorylated Smad2/3 bind a further Smad protein, the 
common-partner Smad4 (Co-Smad) and the formed Smad-complex 
translocates into the nucleus (Fig. 1.4). The heteromeric R-Smad/Smad4 
complexes have been shown to interact directly with specific DNA sequences 
as well as with transcription factors, coactivators and corepressors to regulate 
target genes in a cell-type specific and dose-dependent manner (Heldin et al., 
1997; Derynck and Zhang, 2003; ten Dijke and Hill, 2004). The alternative 
TGF-β type I receptor, ALK-1, can transduce TGF-β1 signals through Smad1, 
5 and 8 at least in endothelial cells (Fig. 1.4) (Roelen et al., 1997; Lux et al., 
1999; Oh et al., 2000). TGF-β1 signalling is controlled by a negative feedback-
loop: TGF-β1 signalling induces expression of inhibitory Smad6/7 (I-Smad), 
which inhibit R-Smad phosphorylation by type I receptors and mark the 
activated type I receptors for degradation or compete with Smad4 in binding 
R-Smads (Fig. 1.4) (Nakao et al., 1997; Heldin et al., 1997; Massague, 2000; 
Massague and Chen, 2000; ten Dijke and Hill, 2004). Classical TGF-β1 
signalling employs the Smad proteins and these are the best-characterised 
transducers of TGF-β1 signalling so far. However, TGF-β1 can also signal 
through other intracellular signalling pathways, especially the mitogen-
activated protein kinase (MAPK) pathway (Massague and Chen, 2000; 
Derynck and Zhang, 2003; Larsson and Karlsson, 2005). 
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Figure 1.4. Schematic presentation of TGF-β1 signalling. 
TGF-β1 transduces its signal through heteromeric complexes of type I and type II receptors, 
which phosphorylate the intracellular R-Smad proteins. R-Smads and the common-partner 
Smad4 complexes translocate to the nucleus and induce transcription of target genes. TGF-
β1 signalling is regulated by inhibitory Smad6/7 through a negative feedback loop. R-Smads 
and Co-Smad4 are shown in green, the inhibitory Smads are shown in red. Modified from 
Larsson and Karlsson, 2005. 
 
1.8.2 TGF-β1 Signalling in Hematopoiesis 
Studying the role of TGF-β1 in hematopoiesis is immensely complicated 
because of its pleiotropic effects also on non-hematopoietic tissues. TGF-β1 
knockout mice have a severe phenotype: around 50% of the mice die during 
embryogenesis due to deficiency in yolk sac circulation and severe 
developmental retardation (Dickson et al., 1995), while the other half survives 
beyond birth owing to maternal transfer of TGF-β1 via the placenta (Shull et 
al., 1992; Kulkarni et al., 1993). The surviving TGF-β1 deficient mice develop 
a wasting syndrome shortly after birth and die at the age of 3-5 weeks 
exhibiting massive inflammatory infiltrates and tissue destruction in several 
organs. The severe phenotype has made it difficult to study TGF-β1 signalling 
in hematopoiesis and HSC function using the knockout mice. Therefore, most 
of the data originate from in vitro cultures and several studies have repeatedly 
shown a growth inhibitory influence of TGF-β1 on HSC and early progenitors 
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both in human and mouse (Fortunel et al., 2000; Larsson and Karlsson, 2005). 
In addition, a similar effect was achieved after local administration of TGF-β1 
into bone marrow (Goey et al., 1989) and ample amount of data from studies 
on human malignancies demonstrate the growth-regulating role of TGF-β1 in 
vivo (Fortunel et al., 2000). Surprisingly then, later studies with inducible type 
II and I TGF-β receptor knockout mice showed similar inflammatory phenotype 
as in TGF-β1 deficient mice but no effect on hematopoiesis in vivo albeit a 
complete block of TGF-β1 signalling (Leveen et al., 2002; Larsson et al., 
2003). It seems that TGF-β1 is not required for the steady state development 
and maintenance of HSC, but indeed has a context-dependent growth-
regulatory effect that is likely influenced by the microenvironment, including 
cytokines and cell-cell contacts. Interestingly, most recent data indicate TGF-
β1 in regulating myeloid-biased versus lymphoid-biased HSC subtypes, being 
stimulatory for myeloid-biased HSC and inhibitory for lymphoid-biased HSC 
(Challen et al., 2010). The role of TGF-β1 under hematopoietic stress, such as 
irradiation or cytotoxic treatments, is still unknown (Larsson and Karlsson, 
2005). 
Similarly, TGF-β1 activity on more mature hematopoietic progenitor cells 
seems to be very much context- and lineage-dependent, depending e.g. on 
the differentiation status of the target cells and the cytokines and their 
concentrations used in the experiments in vitro. In general, more mature 
progenitors are less sensitive to TGF-β1 growth suppressive effect (Fortunel 
et al., 2000; Larsson and Karlsson, 2005). TGF-β1 is a key regulator of 
erythropoiesis, being involved in both early and later stages of erythroid 
progenitor cell development and promoting erythroid differentiation (Fig. 1.5) 
(Fortunel et al., 2000). TGF-β1 has bidirectional effects on granulocytic and 
monocytic/macrophagic cell development being inhibitory on the early bipotent 
myeloid progenitors and stimulatory on the later stages of myelopoiesis (Fig. 
1.5) (Fortunel et al., 2000). In contrast to the differentiation and maturation 
promoting effects of TGF-β1 on other hematopoietic lineages, TGF-β1 seems 
to have only inhibitory activity on megakaryocyte development (Fig. 1.5) 
(Fortunel et al., 2000). Similarly, TGF-β1 has been reported to inhibit pro-B 
cell growth and survival (Kee et al., 2001), whereas TGF-β1 plays a crucial 
role in T cell development and homeostasis (discussed below) (Gorelik and 
Flavell, 2000; Lucas et al., 2000; Gorelik and Flavell, 2002; Marie et al., 2006; 
Sanjabi et al., 2009). 
18 INTRODUCTION 
 
 
Figure 1.5. Regulatory effects of TGF-β1 on the growth and differentiation of 
developmentally distinct hematopoietic cells. 
BFU indicates burst-forming unit; CFU, colony-forming unit; HPP, high proliferative potential; 
DC, dendritic cell; E, erythroid cell; G, granulocyte; M, monocyte/macrophage; and Mk, 
megakaryocyte. Adapted from Fortunel et al., 2000. 
 
1.8.3 TGF-β1 Signalling in Immunity 
TGF-β1 plays a crucial role as immune modulator and its best-known function 
is in maintaining peripheral tolerance largely by influencing T cell development 
and function. This is demonstrated by the similar multi-organ inflammatory 
phenotype of conventional TGF-β1 knockout mice and T cell specific TGF-β1 
knockout mice (Shull et al., 1992; Kulkarni et al., 1993; Gorelik and Flavell, 
2000; Lucas et al., 2000; Marie et al., 2006). TGF-β1 maintains the survival of 
Tregs in the periphery and inhibits proliferation and differentiation of self-
reactive CD4+ and CD8+ T cells. In addition, TGF-β1 is required for natural 
killer T (NKT) cell, Treg cell and CD8+ T cell development in the thymus (Li et 
al., 2006; Marie et al., 2006; Li and Flavell, 2008). TGF-β1 also suppresses 
the cells of the innate immune system. Although blocking of TGF-β1 signalling 
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in these cells, e.g. DC and NK cells, does not cause spontaneous disease in 
steady state, TGF-β1 seems to be important to dampen the function of innate 
immune cells in inflammatory conditions and aberrant TGF-β1 control of these 
cells can have severe pathological consequences (Sanjabi et al., 2009). 
Characteristically for the pleiotropic nature of TGF-β1, it also plays a role 
under inflammatory conditions. TGF-β1 can drive the differentiation of Th17 
cells, which can promote further inflammation and augment autoimmune 
conditions. It can also promote the differentiation of interleukin (IL) 9 and IL-10 
producing T cells that lack suppressive function and promote tissue 
inflammation (Sanjabi et al., 2009). The role of TGF-β1 under inflammatory 
conditions is, however, less well characterised than its immunosuppressive 
functions. 
 
1.8.4 TGF-β1 Signalling in DC Development 
The role of TGF-β1 is well established for LC, which are absent in TGF-β1 
deficient mice (Fig. 1.5) (Borkowski et al., 1996). Most of the TGF-β1 in the 
skin is produced by the abundant keratinocytes, but it has been shown that 
not only paracrine TGF-β1, but also LC-derived autocrine TGF-β1 signalling is 
required for proper LC development (Kaplan et al., 2007). Interestingly, mice 
deficient for the TGF-β1 signalling mediators Id2 and Runx3 are also devoid of 
LC and TGF-β1 induces Id2 expression in human DC (Hacker et al., 2003; 
Fainaru et al., 2004). Hence, TGF-β1 signalling seems to be a key regulator of 
LC development. The frequencies of other DC subsets have not been studied 
in TGF-β1 deficient mice. Id2, on the other hand, has been shown to positively 
regulate lymphoid tissue CD8α+ DC development and to negatively regulate 
pDC development (Table 1.2) (Spits et al., 2000; Hacker et al., 2003). 
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1.9 Aims and objectives 
Hematopoietic lineage development is characterised by consecutive restriction 
steps of multipotent progenitors leading to lineage-committed precursors and 
terminally differentiated cells. These steps are finely regulated by cytokines 
and transcription factors, whose impact depends on the activity of other 
lineage- and developmental stage-specific factors. DC development shows 
remarkable plasticity and DC are difficult to position in traditional lineage 
maps. The current understanding of the molecular mechanisms behind DC 
development is based on studies on terminally differentiated DC by employing 
gene knockout or transgenic mouse models. Recently, DC-lineage restricted 
common DC progenitors have been described (Onai et al., 2007b; Naik et al., 
2007). The very low frequency of CDP in vivo will, however, require specific 
genetic tools or in vitro model systems to address the role of single factors in 
DC development. 
This research aims at investigating the molecular mechanisms underlying DC 
development and DC subset specification, especially the possible role of TGF-
β1 signalling during these events. Therefore, the first objective is to develop a 
culture system that enables the generation of common DC progenitors, CDP, 
and their unlimited differentiation into multiple DC subsets in vitro. Functional 
studies in vitro and in vivo are employed to characterise the in vitro generated 
cells. The molecular events instructing the DC-lineage commitment of CDP 
from multipotent progenitors are analysed with unbiased genome-wide gene 
expression analysis. In addition, the impact of TGF-β1 signalling on DC subset 
specification from CDP employing the developed culture system is addressed. 
TGF-β1 target genes in CDP are analysed with DNA microarray analysis to 
elucidate the molecular mechanisms behind the TGF- β1 activity. Finally, this 
research aims to investigate the role of HLH transcription factor E2A in DC 
subset development and the antagonism of E2A and Id2 by employing mice 
deficient for E2A or Id2. 
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2 Materials and Methods 
2.1 Materials 
If not indicated otherwise, all chemicals were purchased from Sigma or Merck 
in analytical grade. DNA and protein ladder were purchased from Fermentas 
and prepared according to manufacturerʼs instruction. 
 
2.2 Mice 
C57BL/6 (Ly5.2/CD45.2) mice, B6.SJL-Ptprca Pep3b/BoyJ (Ly5.1/CD45.1) 
mice, β-actin-GFP transgenic mice (Okabe et al., 1997), CAR (coxsackie 
adenovirus receptor) transgenic mice (Tallone et al., 2001), CX3CR1-GFP 
knock-in mice (Jung et al., 2000), and E2Afl/fl Vav-Cre mice (Kwon et al., 
2008) are all on C57BL/6 background. Mice were maintained under specific 
pathogen free conditions in the central animal facility of University Hospital 
Aachen. Mice were used for experiments between 7-14 weeks of age. All 
animal experiments were approved by local authorities in compliance with the 
German animal protection law. 
 
2.3 Bone Marrow Transplantations 
Bone marrow transplantations were performed with intravenous (i.v.) tail vein 
injections into lethally irradiated recipient mice. To lethally irradiate mice,  γ-
irradiation was performed using 60Co from a Telecobalt source. A dose of 5.5 
Gy was given twice with 3 h intervals and cells were injected within 2 h after 
the last irradiation. Injections were performed with a 30 G needle using a 100-
200 µl injection volume. Mice were kept under an infrared lamp for 5-10 
minutes before injections to dilate the tail vein. 
For transplantations with amplified progenitor cells, bone marrow cells 
obtained from transgenic GFP mice were cultured in vitro for 7 days with Flt3L, 
SCF, hyper-IL-6 and IGF-1. Cultures were depleted for CD11c+ cells with 
CD11c magnetic beads (Miltenyi Biotec) and 0.2, 0.5, 2 or 5 x 106 GFP+ cells 
were injected i.v. into lethally irradiated wildtype C57BL/6 mice along with a 
radio-protective dose of 5 x 104 wildtype bone marrow cells. At 4 weeks after 
cell transfer, recipient mice were sacrificed. Single-cell suspensions of bone 
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marrow, spleen and thymus were prepared and analysed for donor-derived 
hematopoietic cells by flow cytometry. Three recipients per group were used. 
For bone marrow transplantations with purified MPP and CDP, bone marrow 
cells obtained from CD45.2+ mice were amplified in vitro for 7 days with Flt3L, 
SCF, hyper-IL-6 and IGF-1. MPP and CDP populations were FACS sorted as 
Flt3-/loc-kithiCD11c- and Flt3+c-kitintM-CSFR+CD11c-IL-7Rα- cells, 
respectively. 1 x 106 CD45.2+ cells were injected i.v. into lethally irradiated 
CD45.1+ congenic mice along with a radio-protective dose of 1 x 105 CD45.1+ 
bone marrow cells. At 10 and 28 days after cell transfer, recipient mice were 
sacrificed. Single-cell suspensions of bone marrow and spleen were prepared 
and analysed for donor-derived hematopoietic cells by flow cytometry. Three 
recipients per group were used. 
 
2.4 Cell Culture 
2.4.1 Cell Culture Supplements 
If not indicated otherwise, materials for cell culture were purchased from 
Invitrogen. For all cell cultures heat-inactivated fetal calf serum (FCS; heat-
inactivation for 30 min at 56°C) was used. Cells were grown in a humidified 
incubator at 37°C and 5% CO2. 
 
Table 2.1. Cytokines and growth factors for cell culture. 
Name Company/Source 
Flt3L, human PeproTech 
GM-CSF, human A kind gift from Novartis 
GM-CSF, murine PeproTech 
IGF-1, long-range human Sigma-Aldrich 
IL-4, human A kind gift from Schering-Plough 
IL-6/IL-6 receptor fusion protein  
(hyper-IL-6) 
A kind gift from S. Rose-John, Christian 
Albrect University, Kiel (Fischer et al., 
1997) 
IL-7 Produced by stably transfected J558 cells. 
M-CSF, murine PeproTech 
SCF, murine Produced by stably transfected CHO KLS 
C6 cells. 
TPO Kindly provided by AMGEN 
TGF-β1, human R&D Systems 
 
MATERIALS AND METHODS 23 
 
2.4.2 Culture of Human CD34+ Progenitors and DC 
Human cord blood was taken from umbilical cord after full-term deliveries 
according to institutional guidelines and collected in syringes containing 
heparin. CD34+ hematopoietic stem cells were isolated from human cord 
blood as described (Ju and Zenke, 2003). Briefly, cord blood samples were 
filtered through 70  µm cell strainer and diluted with 4 volumes of PBS. 
Samples were subjected to Ficoll-Hypaque density gradient centrifugation 
(density 1.077 g/ml) (PAA) to obtain mononuclear cells. CD34+ cells were 
isolated by immunomagnetic bead selection using the CD34 Progenitor Cell 
Isolation Kit (Miltenyi Biotec). Cell purity was constantly > 95% CD34+ cells, 
as evaluated by flow cytometry. Cells were resuspended at 0.3-0.5 x 106 
cells/ml and cultured in StemSpan medium (StemCell Technologies) 
supplemented with 100 U/ml penicillin/streptomycin, 50 ng/ml Flt3L, 30 U/ml 
SCF, 20 ng/ml TPO, and 5 ng/ml hyper-IL-6. After 4 days of culture, cell 
density was kept at 1 x 106 cells/ml. Cells were refreshed every second day 
with medium and growth factors. Progenitor cells were harvested at day 7-8. 
To initiate DC differentiation, progenitor cells were washed and cultured 
further at 0.5 x 106 cells/ml in RPMI 1640 supplemented with 10% FCS, 2 mM 
L-glutamine, 100 U/ml penicillin/streptomycin and 50 µM β-mercaptoethanol 
with 500 U/ml IL-4 and 500 U/ml GM-CSF. Half of the medium was replaced 
every second day and growth factors were added to the final concentration. 
DC were used at differentiation day 7-8. 
 
2.4.3 Culture of Mouse Bone Marrow Progenitors 
Bone marrow cell suspension was prepared from femur and tibia by rinsing 
the bones with a 23 G needle. Cells were cultured at 2 x 106 cells/ml in RPMI 
1640 supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin and 50 µM β-mercaptoethanol with 25 ng/ml Flt3L, 30 
U/ml SCF, 5 ng/ml IL-6/soluble IL-6R fusion protein (hyper-IL-6) and 40 ng/ml 
IGF-1. After 3 days of culture cells were subjected to Ficoll-Hypaque density 
gradient centrifugation (density 1.077 g/ml) (PAA) to obtain growth factor 
responsive cells and remove dead cells. Cells were kept at 2 x 106 cells/ml 
concentration and refreshed for medium and cytokines every second day. 
Progenitor cells were harvested at day 7 of culture. 
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When Flt3+CD11b+/GM-CSF DC progenitors were amplified, culture medium 
was supplemented additionally with 25 U/ml GM-CSF and 1 x 10-6 M 
Dexamethasone, as described before (Hieronymus et al., 2005). 
 
2.4.4 Culture of Mouse DC 
DC were generated either with a one-step culture from bone marrow cells or 
with a two-step culture from amplified progenitors. Therefore, bone marrow 
cell suspension (for one-step cultures) or amplified progenitors (for two-step 
cultures) were generated as described above (Chapter 2.4.3). DC were 
cultured at 1 x 106 cells/ml concentration in RPMI 1640 supplemented with 
10% FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin and 50 µM β-
mercaptoethanol. DC differentiation was induced with 50 ng/ml Flt3L, 200 
U/ml GM-CSF or 20 ng/ml M-CSF for 5-10 days. 
 
2.4.5 Culture of B Cells 
B cells were generated in co-cultures with OP9 cells (Nakano et al., 1994). B 
cell medium was  αMEM (PAN Biotech) supplemented with 10% FCS, 100 
U/ml penicillin/streptomycin, 2mM L-glutamine and 100  µM β-
mercaptoethanol with 1% conditioned supernatant from IL-7 producing J558 
cells and 5 ng/ml Flt3L. 
For co-cultures, OP9 cells were seeded 2 days prior to co-culture and cultured 
to achieve 70% confluency. Progenitors or bone marrow cells were seeded at 
2.5 x 105 cells/ml for B cell differentiation. During co-culture, a partial medium 
change was performed every 3 days to refresh half of the culture medium and 
cytokines. B cells were analysed by flow cytometry at day 7-10. 
 
2.4.6 Culture of Cell Lines 
HeLa and HEK293T cells were cultured in Dulbeccoʼs modified Eagle medium 
(DMEM) with 10% FCS, 2 mM L-glutamine and 100 U/ml 
penicillin/streptomycin. OP9 cells were cultured in  αMEM (PAN Biotech) 
supplemented with 20% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin and 100 µM β-mercaptoethanol. Cells were maintained 
under semi-confluent conditions and split at regular intervals with trypsin-
EDTA (0.5%). 
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2.4.7 TGF-β1 Treatments 
Short-term TGF-β1 treatments to investigate the impact of TGF-β1 signalling 
on progenitor cell and DC gene expression were performed with 10 ng/ml 
TGF-β1 with kinetics from 0-36 h. Long term (> 48 h) TGF-β1 treatments were 
performed with 0.1-3 ng/ml TGF-β1. 
TGF-β1 signalling was blocked with a TGF-β1 type I receptor (activin receptor-
like kinase 5; ALK5) inhibitor SB431542 (4-[4-(1,3-benzodioxol-5-yl)-5-(2-
pyridinyl)-1H-imidazol-2-yl]benzamide) (Tocris Bioscience). SB431542 was 
dissolved in DMSO and used at final concentration of 3-5  µM. 
 
2.5 Flow Cytometry 
Analytical flow cytometry was performed using a FACSCalibur™ or 
FACSCanto™ II (BD Biosciences) and data was analysed by FlowJo software 
(Tree Star, Inc.). 
Single cell suspensions from different sources (bone marrow, spleen, thymus, 
cell cultures) were prepared for flow cytometry. Cultured cells from mouse 
bone marrow progenitor cultures were deprived of cytokines and growth 
factors for 2 h before staining. Cells were resuspended in FACS staining 
buffer (PBS supplemented with 1% FCS and 2 mM EDTA) and treated with 
FcR blocking reagent (Miltenyi Biotec) and 3% mouse serum before staining. 
Purified antibodies or antibodies directly conjugated to biotin, FITC, PE, 
PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, APC, APC-Cy7 or Pacific Blue 
were used. Streptavidin-FITC (eBioscience), Streptavidin-PE (Jackson Lab), 
Streptavidin-PerCP-Cy5.5 (BD Bioscience) and Streptavidin-APC 
(eBioscience) were used to detect biotin-conjugated antibodies. Purified 
antibodies were detected with a secondary goat anti-rat antibody conjugated 
to PE (Invitrogen). Cells were incubated with the respective antibody for 30 
min at +4°C. Routinely, staining with the respective isotype (armenian hamster 
IgG, rat IgG2a, rat IgG2b, or streptavidin without primary antibody) and 
fluorochrome was used as control for unspecific staining. Propidium iodide 
(Calbiochem) staining at final concentration of 0.5 µg/ml was used to 
distinguish living and dead cells. 
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Table 2.2. Antibodies for flow cytometry, human. 
Name Alternative name Clone Company 
CD1a  NA1/34 Dako 
CD11b Mac-1 M1/70 eBioscience 
CD11c Integrin-αx B-Ly6 BD Biosciences 
CD34  8G12 Miltenyi Biotec 
HLA-DR MHC II CR3/43 Dako 
CD40  5C30 BD Biosciences 
CD80 B7.BB1 MAB104 Immunotech 
 
Table 2.3. Antibodies for flow cytometry, mouse. 
Name Alternative name Clone Company 
AA4.1 CD93/Ly68 AA4.1 BD Biosciences 
B220 CD45R RA3-6B2 eBioscience 
CD3ε  145-2C11 eBioscience 
CD4 Ly-4 GK1.5 eBioscience 
CD8α Ly-2 53-6.7 eBioscience 
CD11b Mac-1 M1/70 eBioscience 
CD11c Integrin-αx N418 or HL3 eBioscience 
CD19 B4 1D3 eBioscience 
CD24 Heat stable Ag M1/69 eBioscience 
CD45.1 Ly-5.1 A20 BD Biosciences 
CD45.2 Ly-5.2 104 eBioscience 
CD49d Integrin-α4 R1-2 BD Biosciences 
CD49f Integrin-α6 GoH3 BD Biosciences 
CD115 M-CSF receptor AFS98 eBioscience 
CD117 c-Kit ACK2 eBioscience 
CD127 IL-7Rα A7R34 eBioscience 
CD135 Flt3 A2F10.1 eBioscience 
F4/80  CI:A3-1 AbD Serotec 
Lineage Cell Detection 
Cocktail 
  Miltenyi Biotec 
Ly-6A/E Sca-1 D7 Miltenyi Biotec 
Ly-6C/G Gr-1 RB6-C5 BD Bioscience 
MHCII  M5/114.15.2 eBioscience 
PDCA-1  JF05-1C2.4.1 eBioscience 
Siglec-H  440c eBioscience 
Ter119 Ly-76 TER-119 BD Biosciences 
 
Apoptosis in cell cultures was assessed by Annexin V staining according to 
the manufacturerʼs protocol (Annexin V-FITC Apoptosis Detection Kit, BD 
Biosciences). 
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2.6 Cell Sorting 
MPP and CDP were FACS sorted as Flt3lo/-c-kithiCD11c- cells and Flt3+c-
kitintM-CSFR+CD11c-(IL-7Rα-) cells, respectively, at day 7 or 8 of bone 
marrow progenitor culture. Cells were deprived of cytokines and growth 
factors for 1.5 h before staining. pDC and cDC were generated from amplified 
progenitors with Flt3L and sorted as CD11c+CD11b-B220+PDCA-1+ cells and 
CD11c+CD11b+B220-PDCA-1- cells, respectively. For FACS sorting cells 
were stained as described above, filtered through a 40 µm cell strainer and 
resuspended in FACS staining buffer (PBS supplemented with 1% FCS and 2 
mM EDTA) at 1 x 108 cells/ml. 
In vivo CDP were FACS sorted directly from bone marrow. Therefore, single 
cell suspensions from bone marrow of 8-10 mice were prepared and pooled. 
CDP were sorted as lineage negative Flt3+c-kitintM-CSFR+IL-7Rα- cells. 
Biotinylated antibodies against B220, CD11b, Gr-1, CD11c, CD3ε, Ter119 and 
NK1.1 and streptavidin-FITC were used to stain lineage positive cells. 
Cell sorting was performed with FACSAria™ device (BD Biosciences). Cells 
were collected in FACS collection buffer (1x HBSS (purchased from 
Invitrogen) containing 1% FCS and 100 µg/ml Gentamycin). After sorting, cells 
were washed with PBS and either lysed for RNA, cultured further or used for 
bone marrow transplantations. 
 
2.7 Colony Forming Cell Assay 
MPP and CDP were sorted as Flt3lo/-c-kithiCD11c- cells and Flt3+c-kitintM-
CSFR+CD11c-(IL-7Rα-) cells, respectively, at day 7 or 8 of culture. Sorted 
progenitors were plated in semisolid methylcellulose (MethoCult® GF M3434, 
StemCell Technologies) containing insulin, transferrin, SCF, IL-3, IL-6 and 
erythropoietin at 5000 cells/ml concentration. Colonies were evaluated under 
microscope at day 6-8: colonies consisting of (i) more than 40 cells were 
counted for MPP, (ii) more than 10 cells were counted for CDP. 
Representative colonies were picked at day 8 or 10 and cytospins were 
stained with Diff/Quick (DADE Behring). Erythroid differentiation was 
assessed by neutral benzidine staining (Beug et al., 1982). Photographs were 
taken with Axiopan 2 microscope (Carl Zeiss) using Scion digital camera 
CFW-1312C (Scion Corporation). Image processing was done with Photoshop 
CS software (Adobe). 
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2.8 Cell Proliferation with CFSE Labelling 
For monitoring cell proliferation, cells were labelled with carboxyfluorescein 
diacetate succinimidyl ester (CFSE) (Molecular Probes). Briefly, amplified 
progenitors at day 7 were washed and resuspended in PBS at 1 x 107 
cells/ml. Labelling was performed with 3.5 µM CFSE for 10 min at 37°C and 
stopped by addition of culture medium. Cells were washed twice, cultured 
further as described above (2.4.3) and analysed by flow cytometry 24, 48 and 
72 h after labelling. Cell numbers were determined with an electronic cell 
counter device (CASY1; Schärfe Systems). 
 
2.9 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated using RNeasy Midi or Mini Kit with DNaseI digestion 
(Qiagen) according to the manufacturerʼs protocol. RNA concentration was 
measured by spectrophotometry using a NanoDrop devise (Thermo 
Scientific). Reverse transcription reaction was performed with 1  µg of RNA 
using High Capacity cDNA RT Kit (Applied Biosystems). 
Semi-quantitative PCR was performed with 50 ng of cDNA using an 
Eppendorf Master cycler (Eppendorf). All reagents for PCR reactions were 
purchased from Fermentas. Primer sequences for semi-quantitative PCR 
analysis are listed in Tables 2.4 and 2.5. PCR products were resolved on 2% 
agarose gels. 
 
Table 2.4. Primers for semi-quantitative RT-PCR, human. 
Gene Primer pairs  
(5ʼ → 3ʼ) 
GAPDH for AAG GTG AAG GTC GGA GTC AA 
GAPDH rev GCC AGT GGA CTC CAC GAC GT 
IRF-8 for CAG TGG CTG ATC GAG CAG ATT GA 
IRF-8 rev ATT CAC GCA GCC AGC AGT TGC CA 
Smad7 for TCC TCC TTAC TCC AGA TAC CCA ATG 
Smad7 rev GCA GGC TGT AGG CTT TCT CAT AGT C 
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Table 2.5. Primers for semi-quantitative RT-PCR, mouse. 
Gene Primer pairs  
(5ʼ → 3ʼ) 
Reference 
β-actin for CCA ACC GTG AAA AGA TGA CC  
β-actin rev CCA GAG GCA TAC AGG GAC AG  
c-kit for AGG AGA TAA ATG GAA ACA ATT ATG T 
c-kit rev CTT CCT TGA TCA TCT TGT AGA ACT T 
(Peters et al., 
2003) 
CSF-1R for ATG AGT CCC TCT TCA CTC CG  
CSF-1R rev ACC TTC AGC ACT GCA TCT TC  
CEBPα for GGT GGA CAA GAA CAG CAA CGA G  
CEBPα rev TAG AGA TCC AGC GAC CCG AAA C  
Flt3 for TCT TGA GAC CGT TAC AAA CC 
Flt3 rev ATG TCT GTT CCG AAC AAC TC 
(Carotta et al., 
2004) 
GAPDH for GGG GTG AGG CCG GTG CTG AGT AT  
GAPDH rev CAT TGG GGG TAG GAA CAC GGA AGG  
GATA-2 for ACA CAC CAC CCG ATA CCC ACC TAT 
GATA-2 rev CCT ACG CCA TGG CAG TCA CCA TGC T 
(de Pooter et al., 
2006) 
HPRT for GCT TGC TGG TGA AAA GGA CCT C  
HPRT rev TCA AAA GTC TGG GGA CGC AG  
Id1 for CC TGC TCT ACG ACA TGA ACG  
Id1 rev TCC TCA GAA ATC CGA GAA GC  
Id2 for ATC CGC TCG AGT CCC CAG CAT GCC TGC  
Id2 rev CGT GTT CTC CTG GTG AAA TGG  
Id3 for GCA CTG TTT GCT GCT TTA GG  
Id3 rev AGA TCG AAG CTC ATC CAT GC  
IRF-4 for GCT GCA TAT CTG CCT GTA TTA CCG 
IRF-4 rev GTG GTA ACG TGT TCA GGT AAC TCG TAG 
(Marecki et al., 
1999) 
IRF-8 for CGT GGA AGA CGA GGT TAC GCT G  
IRF-8 rev GCT CAC TGG GGA TGG TGT CG  
Langerin for AAG AGT GAT GCC CAG ATG TTG AAA 
Langerin rev TTG GGG TGC GTG AAA AGT AAT AGA 
(Mende et al., 
2006) 
RelB for GGT GAC GGC GTG CCT GGT GTG  
RelB rev ACG GCC CGC TCT CCT TGT TGA TTC  
Smad7 for TCC TCC TTA CTC CAG ATA CCC AAT G  
Smad7 rev GCA GGC TGT AGG CTT TCT CAT AGT C  
Tcf4 for GGT ACA GAC  AAA GAA AGT CC  
Tcf4 rev GAG AAT AGA TCG AAG CTA GG  
TLR7 for CCA CCA  GAC CTC TTG ATT CC  
TLR7 rev CGT GTC CAC ATC GAA AAC ACC  
 
2.10 DNA Microarrays 
Total RNA was isolated using RNeasy Mini or Micro Kit with DNaseI digestion 
(Qiagen) according to the manufacturerʼs protocol and subjected to microarray 
analysis as described before (Hacker et al., 2003; Hieronymus et al., 2005). 
Briefly, sample preparation was performed according to Expression Analysis 
Technical Manual (Affymetrix). GeneChip One-cycle Target Labelling Kit 
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(Affymetrix) and 1  µg of total RNA were used for in vitro generated MPP, 
CDP, cDC and pDC samples. GeneChip 3`IVT Express Kit (Affymetrix) and 50 
ng or 250 ng of total RNA were used for in vivo CDPs and samples of TGF-β1 
kinetics, respectively. Biotin-labelled cRNA was hybridised on Affymetrix 
Mouse Genome 430 2.0 arrays. GeneChip arrays were stained, washed and 
scanned according to the manufacturerʼs protocol. 
Gene expression levels were determined by GCRMA algorithm in 
R/Bioconductor (Gentleman et al., 2004). Principal component analysis (PCA) 
was done by prcomp in R package stats. Hierarchical clustering was 
performed using Pearson correlation coefficient and the Average linkage 
method, and represented by dendrogram and/or heatmap. Differential 
expression between two conditions was analyzed using student's t-tests. The 
transcripts with a fold change more than 2 and p-value less than 0.05 were 
considered as being differentially expressed. Raw p-values were adjusted by 
Benjamini and Hochberg's method (Benjamini and Hochberg, 1995). 
For TGF-β1 data sets the differentially expressed transcripts were detected 
between any two time-points. Fuzzy c-means algorithm in R/Bioconductor 
package Mfuzz (Kumar and M, 2007) was applied in order to reveal the gene 
expression pattern in TGF-β1 kinetics data. Specifically, for each time point (0, 
4, 8, 12 and 24 h), the gene expression values of the biological replicates 
were averaged. Then the differentially expressed transcripts with averaged 
expression were clustered by Fuzzy c-means algorithm with parameter k = 6 
and m = 2 (Kumar and M, 2007). The algorithm was performed on 100 
independent runs, and the one with highest silhouette values was selected 
(Rousseeuw, 1987; Kumar and M, 2007). The R/Bioconductor package 
GOstats (Alexa et al., 2006) was utilized for Gene Ontology (GO) (Ashburner 
et al., 2000) enrichment analysis. 
Data sets were submitted to Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo; accession number GSE22432). 
Preparation of microarray chips was performed by Christiane Becker and 
Saskia Mitzka (Institute for Biomedical Engineering, Cell Biology, RWTH 
Aachen University, Aachen, Germany). Affymetrix GeneChip hybridisations 
were performed at Chip Facility (IZKF, RWTH Aachen University, Aachen, 
Germany) and bioinformatic analysis was performed in collaboration with 
Qiong Lin (Institute for Biomedical Engineering, Cell Biology, RWTH Aachen 
University, Aachen, Germany). 
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2.11 Western Immunoblotting 
2.11.1 Cell Lysate Preparation for Proteins 
For lysis, cell were kept on ice and washed twice with cold PBS. Cells were 
lysed in sample buffer (62.5 mM Tris/HCl, pH 6.8, 10% Glycerol, 2% SDS, 1% 
(v/v)  β-mercaptoethanol, 0.0005% (w/w) Bromphenol Blue). All lysates in 
sample buffer were heated for 5 min at 95°C and stored at -80°C. 
 
2.11.2 SDS Polyacrylamid Electrophoresis (SDS-PAGE) 
Proteins were separated on SDS-gels. SDS gels were prepared using a Mini-
Protean Tetra Cell apparatus (Bio-Rad). Briefly, 10% separation gels were 
prepared of 12.45 ml of H2O, 7.5 ml separation gel buffer (1.5 M Tris/HCl, pH 
8.8, 0.4% SDS), 9.9 ml 30% acryl amide (Bio-Rad), 150  µl 10% ammonium 
per-sulfate (APS, Bio-Rad), 45 µl TEMED. Stacking gels were prepared of 9 
ml H2O, 3.76 ml stacking gel buffer (0.5 M Tris/HCl, pH 6.8, 0.4% SDS), 2.1 
ml 30% acryl amide, 44  µl 10% ammonium per-sulfate, 14 µl TEMED. 0.75-1 
x 106 cells per lane were loaded on the gels. SDS-PAGE was carried out at 30 
mA for 60 min in SDS running buffer (25 mM Tris base, 250 mM Glycin, 0.1% 
SDS) and gels were subjected to Western blotting. 
 
2.11.3 Western Immunoblotting  
Proteins in SDS gels were blotted on a membrane (PVDF; Pierce) by a semi-
dry blotting procedure. Briefly, filter paper, gel, and membrane were soaked in 
transfer buffer (48 mM Trisma Base, 39 mM glycine, 0.03% SDS, 20% 
methanol) and assembled. Blotting was carried out at 150 mA for 1.5 hours 
with a semi-dry blotting device (Multiphor II, Pharmacia Biotech). For 
immunolabeling, blots were blocked in 3% milk (delipidated dry milk; Nestle 
Carnation) in TBS-T (25 mM Tris/HCl, pH 7.4, 147 mM sodium chloride, 2.7 
mM potassium chloride, 0.1% Tween 20) over night at 4°C. Blots were stained 
with rabbit polyclonal antibodies against Smad2/3 (Cell Signaling Technology), 
phospho-Smad2/3 (Ser465/467; Cell Signaling Technology), Smad7 (H-79; 
Santa Cruz Biotechnology), IRF-8/ICSBP (C-19; Santa Cruz Biotechnology) or 
mouse anti-actin monoclonal antibody (Sigma-Aldrich). Blots were incubated 
with primary antibodies in 3% milk/TBS-T for 45-60 min hour at room 
temperature, following 3 washing steps with TBS-T for 10 min each on a 
rocking platform. Blots were then incubated with respective secondary 
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antibody coupled with horseradish-peroxidase (Amersham) in 3% milk/TBS-T 
for 1 hour at room temperature. After washing blots as before, blots were 
incubated with ECL reagent (Pierce) and exposed to film or developed with a 
chemiluminescence sensitive camera (LAS-3000, Fujifilm). 
 
2.12 ELISA 
TGF- β1 in cell culture media was detected by ELISA immunoassay (Human 
TGF- β1 Quantikine, R&D Systems) according to the manufacturerʼs 
protocol. Latent TGF- β1 was activated to immunoreactive TGF- β1 by 
acidification as described in the protocol. 
 
2.13 Adenovirus Infections 
For adenovirus infections, Flt3+CD11b+/GM-CSF DC progenitors were 
obtained from transgenic CAR mice (as described in Chapter 2.4.3). Cells 
were plated in 24-well-plates at 20 x 106 cells/ml. Recombinant Smad7 
adenovirus or recombinant GFP control virus (kindly provided by S. Dooley, 
Heidelberg, Germany) (Dooley et al., 2003), both serotype 5, were added at 
40-80 pfu/cell concentration. Cells were incubated with the virus for 2 h at 
37°C, gently agitating the plate every 20-30 min. After 2 h, cells were 
transferred into 6-well plates and cell concentration was adjusted to 2 x 106 
cells/ml. Cells were harvested and analysed after 16-24 h by flow cytometry, 
Western immunoblotting or RT-PCR. 
 
2.14 Statistical Analysis 
Numerical data were analysed for significance by a two-tailed and unpaired 
Studentʼs t test with GraphPad Prism software (GraphPad Software Inc.). P 
values below 0.05 were considered to be significant. 
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3 Results 
3.1 Steady State vs. Inflammatory DC Development in vitro 
DC are frequently generated in vitro from mouse bone marrow by cultivation 
with Flt3L or GM-CSF (Brasel et al., 2000; Brawand et al., 2002; Gilliet et al., 
2002; Naik et al., 2005; Inaba et al., 1992). Bone marrow cultures with Flt3L 
induce differentiation into three DC subsets: CD11c+CD11b-B220+ pDC, 
CD11c+CD11bloCD24hi CD8α-like cDC and CD11c+CD11bhiCD24lo cDC 
(here called CD11bhi cDC) (Fig. 3.1A). The DC subsets generated with Flt3L 
are regarded as in vitro equivalents for lymphoid tissue DC as found for 
example in spleen (Naik et al., 2005). The CD11c+CD11bloCD24hi cDC do not 
express CD8α in vitro, hence they are referred to as CD8α-like cDC, but 
otherwise resemble the in vivo CD8α+ cDC in their surface marker repertoire 
and upregulate CD8α upon activation with LPS or when injected into mice 
(Brasel et al., 2000; Naik et al., 2005). 
Bone marrow cultures with GM-CSF effectively induce differentiation into 
CD11c+CD11b+ DC that also express CD24 and the myeloid marker F4/80 
(Fig. 3.1B). However, GM-CSF inhibits pDC development (Esashi et al., 2008) 
and only gives rise to DC that are considered to represent inflammatory DC 
with no in vivo counterpart in steady state (Naik et al., 2006; Shortman and 
Naik, 2007). Hence, GM-CSF cultures do not allow the investigation of steady 
state DC differentiation or DC subset specification. 
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Figure 3.1. DC differentiation from bone marrow with Flt3L and GM-CSF. 
(A) Bone marrow cells were cultured with Flt3L for 6 days and analysed for DC subsets by 
flow cytometry. pDC were analysed as CD11c+CD11b-B220+, CD11bhi cDC as 
CD11c+CD11bhiCD24lo and CD8α-like cDC as CD11c+CD11bloCD24hi cells. Numbers next 
to gates depict percentages of parent populations. (B) Bone marrow cells were cultured with 
GM-CSF for 8 days and analysed for expression of CD11c, CD11b, CD24 and F4/80 by flow 
cytometry. Closed histograms, isotype control; open histograms, staining with antibody as 
indicated. 
 
Although recapitulating lymphoid tissue DC development, one-step Flt3L 
cultures undergo an initial selection phase for Flt3L-responsive cells that leads 
to massive cell death and a drop in cell numbers during the first 5 days of 
culture ((Naik et al., 2007) and data not shown). DC committed progenitors are 
found in the culture at day 3-3.5 and after the selection phase initial steps in 
DC differentiation have already taken place (Naik et al., 2007). As the goal of 
this thesis was to investigate DC development including the early steps of DC 
commitment and subset specification, one-step Flt3L cultures are not a 
suitable system to address this question. 
A two-step culture system for progressive and controlled DC differentiation 
from amplified progenitors was previously described (Hieronymus et al., 
2005). This culture system enables efficient amplification of Flt3+CD11b+ 
progenitors from bone marrow and their subsequent differentiation into DC 
with GM-CSF. The differentiation potential of Flt3+CD11b+ progenitors into 
multiple DC subsets in response to Flt3L was tested here (Fig. 3.2). While 
being able to generate CD11bhi cDCs and CD8α-like cDCs, Flt3+CD11b+ 
progenitors were devoid of pDC potential. Thus, a new, unrestricted culture 
system was required for investigation of early DC development into multiple 
subsets. 
 
Figure 3.2. DC differentiation into multiple subsets from Flt3+CD11b+ progenitors with 
Flt3L. 
Flt3+CD11b+ progenitors were amplified for 7 days from bone marrow with Flt3L, SCF, hyper-
IL-6, IGF-1, GM-CSF and Dexamethasone as described before (Hieronymus et al., 2005). DC 
differentiation was induced with Flt3L and cells were analysed by flow cytometry for DC 
subsets at day 10 of differentiation. pDC were analysed as CD11c+CD11b-B220+, CD11bhi 
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cDC as CD11c+CD11bhiCD24lo and CD8α-like cDC as CD11c+CD11bloCD24hi cells. 
Numbers next to gates depict percentages of parent population. 
 
3.2 Amplification of Multipotent Progenitors from Bone Marrow 
3.2.1 Morphology and Growth of Amplified Progenitors 
Mouse bone marrow cells were cultured in the presence of Flt3L, SCF, hyper-
IL-6 and IGF-1. The culture induced propagation of cells that showed typical 
progenitor cell morphology with large nucleus and little cytoplasm (Fig. 3.3A). 
Cells were growing exponentially for at least 2 weeks, as shown by cumulative 
cells numbers (Fig. 3.3B), and cells divided synchronously, as demonstrated 
by continuous and synchronous dilution of cytosolic CFSE label (Fig. 3.3C). 
 
 
Figure 3.3 Growth and morphology of in vitro amplified bone marrow progenitors. 
Bone marrow cells were amplified with Flt3L, SCF, hyper-IL-6 and IGF-1. (A) Morphology of 
the amplified progenitors at day 7, stained with May-Gruenwald/Giemsa. Scale bar in inset 10 
 µm. (B) Cumulative cell numbers were determined at regular time intervals and are depicted. 
(C) Progenitors were labelled with CFSE at day 7 and cultured further under amplification 
conditions. Cells were analysed by flow cytometry 1, 2, and 3 days later. 
 
To investigate the impact of cytokines and growth factors on proliferation, 
Flt3L, SCF, hyper-IL-6 and IGF-1 were added individually or in different 
combinations on the amplified progenitors at day 7 (Fig. 3.4). The most 
pronounced response in proliferation was measured for cytokine cocktails 
containing Flt3L. Cultures with Flt3L alone showed only moderate proliferation 
probably due to the DC differentiation inducing effect of Flt3L. SCF, hyper-IL-6 
and IGF-1 alone had a poor proliferative activity on the amplified progenitors. 
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Figure 3.4. Growth factor response of in vitro amplified bone marrow progenitors. 
Bone marrow cells were cultured with Flt3L, SCF, hyper-IL-6 and IGF-1 for 7 days. Cells were 
deprived of growth factors for 6h before individual factors and various combinations thereof 
were added as indicated and cell numbers were determined 72 h later. Starting cell number 2 
x 106 cells. Results are mean of triplicate values ± SD. Four factors, 4F; three factors, 3F; two 
factors, 2F; one factor, 1F. 
 
Flow cytometry analysis of the amplified progenitors at day 7 showed 
expression of several stem/progenitor cell surface antigens, such as c-kit and 
Flt3, the receptors for SCF and Flt3L, respectively (Fig. 3.5). Flt3hi and Flt3-/lo 
populations were observed. The stem cell markers α4 and α6 integrins, 
CD49d and CD49f, respectively, AA4.1/CD93 and CD24 were uniformly 
expressed (Fig. 3.5 and Table 3.1). Hence, the surface antigen repertoire of 
the amplified progenitors resembles that of multipotent hematopoietic 
stem/progenitor cells. However, the amplified progenitors differed from stem 
cells. For instance, the progenitors expressed CD11b (Mac-1), which is 
considered to be a myeloid lineage marker (Fig. 3.5). 
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Figure 3.5. Immunophenotype of in vitro amplified bone marrow progenitors. 
c-kit, Flt3, CD49f, AA4.1, CD24, and CD11b expression on progenitors at day 7 of culture, 
analysed by flow cytometry. Closed histograms, isotype control; open histograms, staining 
with antibody. 
 
Table 3.1. Surface phenotype of in vitro amplified progenitors. 
Surface marker Alternative Name mAb clone Expression 
AA4.1 CD93/Ly68 AA4.1 + 
CD11b Mac-1 M1/70 ++ 
CD11c Integrin-αx N418/HL3 -/+ 
CD24 Heat stable antigen M1/69 +++ 
CD45R B220 RA3-6B2 -/+ 
CD49d Integrin- α4 R1-2 +++ 
CD49f Integrin-α6 GoH3 +++ 
CD115 M-CSF receptor AFS98 -/+++* 
CD117 c-kit ACK-2 ++/+++ 
CD135 Flt3 A2F10.1 -/++** 
CX3CR1 Fractalkine receptor - +/++ 
Ly6A/E Sca-1 D7 -/+ 
Ly6C/G Gr-1 RB6-C5 -/++** 
 
In vitro amplified bone marrow cells were analysed by flow cytometry at day 7. Data shown 
are representative for at least three independent experiments. Expression levels were high 
(+++), intermediate (++), low (+) or negative (-). * M-CSF receptor expression was from 
low/negative to very high. ** Flt3 and Gr-1 showed two populations with no/low or intermediate 
expression levels. 
 
3.2.2 In vivo Differentiation Potential of Amplified Progenitors 
To investigate the in vivo differentiation potential of the amplified progenitors, 
progenitors generated from transgenic GFP mice were transferred into lethally 
irradiated wildtype recipients. Bone marrow, spleen and thymus of recipient 
mice were analysed for donor-derived hematopoietic cells 4 weeks after 
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transfer. GFP+ donor-derived progenitors showed high engraftment in all 
analysed organs, particularly in spleen and thymus (Fig. 3.6). Engraftment 
was dose-dependent, i.e. highest engraftment was observed with 5 x 106 cells 
and declined with decreasing cell numbers injected. The amplified progenitors 
gave rise to all hematopoietic lineages, which demonstrates their multilineage 
potential (Fig. 3.7). The percentage of GFP+ donor-derived progeny was 
particularly high for B cells, monocytes and DC, whereas erythrocyte and T 
cell potential was somewhat lower (Fig. 3.7). Taken together, the growth 
conditions with Flt3L, SCF, hyper-IL-6 and IGF-1 promoted generation of large 
numbers of multipotent progenitors from mouse bone marrow. Importantly, the 
amplified progenitors gave rise to all lymphoid tissue DC subsets, including 
pDC, in vivo  (Fig. 3.7 and 3.8). 
 
 
Figure 3.6. Engraftment of amplified progenitors in vivo. 
In vitro amplified bone marrow progenitors were generated from transgenic GFP mice, 
depleted for CD11c+ cells by MACS and used for transplantation into lethally irradiated 
wildtype recipient mice. Single cell suspensions of bone marrow, spleen and thymus were 
analysed for GFP+ donor-derived cells 4 weeks after transplantation. Three mice per group 
were used. Results represent mean values ± SD. 
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Figure 3.7. In vivo potential of amplified bone marrow progenitors. 
In vitro amplified bone marrow progenitors were generated from transgenic GFP mice, 
depleted for CD11c+ cells by MACS and used for transplantation into lethally irradiated 
wildtype recipient mice along with a radio-protective dose of wildtype bone marrow. Single cell 
suspensions of bone marrow and spleen (A and B, respectively) were analysed for GFP+ 
donor-derived hematopoietic cells 4 weeks after transplantation. (A) GFP+ donor-derived 
erythrocytes (Ter119+), B cells (CD19+), macrophages (F4/80+), monocytes/macrophages 
(CD11b+) in bone marrow. CD11b+ cells were further characterised for monocyte markers 
CD115 and Gr-1. (B) GFP+ donor-derived T cells (CD3ε+) and DC (CD11c+) in spleen. T 
cells were further divided into CD4+ and CD8α+ subsets. DC were further divided into pDC 
(CD11b-B220+PDCA-1+) and CD4+ and CD8α+ cDC subsets. Numbers next to gates depict 
40 RESULTS 
 
percentages from parent populations. Representative results from 2 x 106 injected progenitors 
are shown. Three mice per group were used. 
 
 
Figure 3.8. Progenitor-derived DC in spleen and thymus. 
Single cell suspensions of spleen and thymus were analysed for GFP+ donor-derived DC 
(CD11c+). DC in spleen were further divided into CD11b-B220+PDCA-1+ pDC, CD4+ cDC 
and CD8α+ cDC. Data from 2 x 106 injected progenitors are shown. Results are mean of 
triplicate values ± SD. 
 
3.2.3 DC Differentiation In vitro from Amplified Progenitors 
To ensure that the amplified progenitors possess the full DC differentiation 
potential in vitro, I tested their differentiation in Flt3L conditions. The amplified 
progenitors gave rise to all DC subsets, including pDC, in response to Flt3L 
(Fig. 3.9). The in vitro DC differentiation kinetics was somewhat faster from 
the amplified progenitors compared to whole bone marrow (approximately 6 
days and 8 days, respectively, data not shown). This is probably due to the 
pre-selection for Flt3L responsive cells in the progenitor culture (as seen in 
Fig. 3.5 for Flt3 expression and Fig. 3.4 as proliferation response to Flt3L), 
whereas the one-step culture goes through an initial selection phase 
(discussed above). 
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Figure 3.9. DC subset development from amplified progenitors with Flt3L. 
Bone marrow cells were cultured with Flt3L, SCF, hyper-IL-6 and IGF-1. DC differentiation 
from day 7 progenitors was induced by replacing the amplification cytokine cocktail with Flt3L. 
DC subsets were analysed at day 10 as: CD11c+CD11b-B220+ (pDC), 
CD11c+CD11bloCD24hi (CD8α-like DC) and CD11c+CD11bhiCD24lo (CD11bhi cDC). 
Numbers next to gates depict percentages of parent population. 
 
3.3 Common Dendritic Cell Progenitor 
3.3.1 Amplified Progenitor Culture Comprises Multipotent Progenitors (MPP) 
and Common DC Progenitors (CDP) 
The amplified progenitor culture comprises Flt3hi and Flt3-/lo populations (Fig. 
3.5) and thus cells that express the receptor tyrosine kinase important for DC 
development. In addition, spontaneous differentiation into CD11c+ DC was 
observed, which increased with culture time: at day 5 essentially no CD11c+ 
cells were measured whereas at day 7 the CD11c+ cells constituted 
approximately 10% of the total culture (Fig. 3.10). 
 
 
Figure 3.10. Spontaneous differentiation into CD11c+ cells under amplification 
conditions. 
Bone marrow cells were cultured with Flt3L, SCF, hyper-IL-6 and IGF-1. CD11c expression 
was analysed by flow cytometry at day 5 and 7. Closed histogram, isotype control; open 
histogram, staining with antibody. 
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Moreover, in vivo transplantation experiments showed high percentages of 
progenitor-derived DC in all DC subsets (Fig. 3.7 and 3.8). Thus, the amplified 
progenitors seemed to be very susceptible to DC differentiation. Therefore, the 
progenitor cultures were analysed for the presence of the recently described 
common DC progenitor (CDP) (Onai et al., 2007b; Naik et al., 2007). Indeed, a 
Flt3+c-kitintM-CSFR+IL-7Rα- population was found, which also expressed the 
chemokine receptor CX3CR1 (Fig. 3.11A) (Waskow et al., 2008). Thus, based 
on the surface marker expression and the differentiation potential of the cells 
(see below) this cell population will be referred to as CDP. 
In addition, the culture contained a population of Flt3-/loc-kithi cells (Fig. 
3.11A). High c-kit expression correlates with immature stem/progenitor cell 
phenotype and Flt3-/loc-kithi cells were found to exhibit multilineage 
differentiation potential (see below) and the Flt3-/loc-kithi cell population will 
hereafter be referred to as multipotent progenitors (MPP). Importantly, the in 
vitro CDP and MPP obtained in this culture system resembled their in vivo 
counterparts from bone marrow in their surface marker repertoire (Fig. 3.11B). 
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Figure 3.11. MPP and CDP populations in vitro and in vivo. 
In vitro amplified bone marrow progenitors and lineage negative bone marrow cells from 
CX3CR1gfp/+ mice (A and B, respectively) were stained for c-kit, Flt3, M-CSFR/CD115 and 
IL-7R α/CD127 and analysed by flow cytometry. In vitro culture contained Flt3-/loc-kithi MPP 
and Flt3+c-kitintM-CSFR+ CDP, which showed a similar surface marker profile as MPP and 
CDP from bone marrow. Numbers next to gate depict percentages of parent population. Data 
shown are representative of at least three independent experiments. 
 
3.3.2 CDP Have Restricted Developmental Potential 
CDP were described as DC committed progenitors with low remaining 
macrophage potential and no capacity to give rise to other hematopoietic 
lineages (Onai et al., 2007b; Naik et al., 2007). To investigate the 
differentiation potential of the in vitro generated MPP and CDP, cells were 
subjected to FACS sorting (Fig. 3.12A) and in vitro colony formation assay 
containing insulin, transferrin, SCF, IL-3, IL-6 and erythropoietin. Generated 
colonies were evaluated by microscopy and histological staining. Six days 
after seeding, MPP had generated 80±4 colonies per 5000 cells seeded (> 40 
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cells/colony) (Fig. 3.12B and C). Granulocyte (CFU-G), macrophage (CFU-M), 
mixed granulocyte/macrophage colonies (CFU-GM) and a low number of 
mixed colonies with granulocytes, erythrocytes, macrophages and 
megakaryocytes (CFU-GEMM) were found (Fig. 3.12B and C). On the 
contrary, number of colonies from CDP was 10 times lower than from MPP 
and CDP-derived colonies were smaller in size (in average 7 colonies 
comprising 10-20 cells per 5000 cells). All colonies generated from CDP were 
CFU-M (Fig. 3.12B and D). 
 
 
Figure 3.12. In vitro developmental potential of MPP and CDP.  
In vitro amplified MPP and CDP progenitors were FACS sorted at day 8 (A) and seeded in 
semisolid methylcellulose (B-D). (B) Colonies consisting of more than 40 cells were scored for 
CFU-M, CFU-G, CFU-GM and CFU-GEMM phenotype at day 6 (MPP). CDP generated 
colonies of 10-20 cells in size and colonies containing more than 10 cells were considered 
(CDP). The CFU-GEMM colonies rarely turned red and were phenotypically indistinguishable 
from mixed CFU-GM colonies (at day 6) and the CFU-GM numbers shown comprise both 
CFU-GM and CFU-GEMM. (C) Colonies were picked at day 8 and cytospins were stained 
with Diff/Quick. Erythroid differentiation was assessed by neutral benzidine staining. 
Representative images of CFU-M, CFU-G, CFU-GM and CFU-GEMM are shown. Original 
magnification, 200X. Inset for erythroid cells in CFU-GEMM. Original magnification, 400X. (D) 
Phase contrast image of representative colony from CDP with CFU-M morphology. Original 
magnification, 200X. All experiments were repeated at least once with similar results. Colony-
forming unit (CFU) macrophage, CFU-M; CFU-granulocyte, CFU-G; CFU-macrophage 
/granulocyte, CFU-GM; CFU-granulocyte/erythrocyte/macrophage/megakaryocyte, CFU-
GEMM. 
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Next, I analysed the differentiation potential of MPP and CDP in vivo after 
transfer into lethally irradiated recipients. Therefore, progenitors were 
amplified from bone marrow of CD45.2+ mice, MPP and CDP were FACS 
sorted and transferred into CD45.1+ recipients. In line with the in vitro 
developmental potential in the colony formation assay (Fig. 3.12) and similar 
to the in vivo transplantation assay of the unsorted culture (Fig. 3.7), MPP 
showed multilineage developmental potential and had high engraftment in 
bone marrow and spleen (Fig. 3.13). On the contrary, CDP progeny was very 
scarce 4 weeks after transplantation in comparison to MPP progeny (0.29% 
vs. 31.2% in bone marrow and 4.02% vs. 55.3% in spleen), (Fig. 3.13 and 
3.14). The limited remaining CDP progeny consisted mainly of B cells. 
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Figure 3.13. Differentiation potential of MPP into myeloid and lymphoid lineages in 
vivo. 
In vitro amplified bone marrow progenitors were obtained from CD45.2+ mice. MPP were 
sorted by FACS as Flt3-/loc-kithiCD11c- cells and 106 cells were used for transplantation into 
lethally irradiated CD45.1+ recipient mice along with a radio-protective dose of CD45.1+ bone 
marrow. Single cell suspensions of bone marrow and spleen (A and B, respectively) were 
analysed for CD45.2+ donor-derived hematopoietic cells 4 weeks after transplantation. (A) 
CD45.2+ donor-derived macrophages (CD11b+CD115-), monocytes (CD11b+CD115+) and B 
cells (CD11b-CD19+) in bone marrow. CD11b+CD115+ monocytes were further 
characterised for Gr-1 expression. (B) CD45.2+ donor-derived macrophages (CD11b+CD115-
), monocytes (CD11b+CD115+), B cells (CD19+), T cells (CD3ε+) and DC (CD11c+PDCA-1- 
cDC and CD11c+PDCA-1+ pDC) in spleen. CD11b+CD115+ monocytes were further 
characterised for Gr-1 expression. Numbers next to gate depict percentages of parent 
population. Representative results are shown. Three mice per group were used. 
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Figure 3.14. Differentiation potential of CDP into myeloid and lymphoid lineages in 
vivo. 
In vitro amplified bone marrow progenitors were obtained from CD45.2+ mice. CDP were 
sorted by FACS as Flt3+c-kitintM-CSFR+CD11c-IL-7Rα- cells and 106 cells were used for 
transplantation into lethally irradiated CD45.1+ recipient mice along with a radio-protective 
dose of CD45.1+ bone marrow. Single cell suspensions of bone marrow and spleen (A and B, 
respectively) were analysed for CD45.2+ donor-derived hematopoietic cells 4 weeks after 
transplantation. (A) CD45.2+ donor-derived macrophages (CD11b+CD115-), monocytes 
(CD11b+CD115+) and B cells (CD11b-CD19+) in bone marrow. (B) CD45.2+ donor-derived 
macrophages (CD11b+CD115-), monocytes (CD11b+CD115+), B cells (CD19+), T cells 
(CD3ε+) and DC (CD11c+PDCA-1- cDC and CD11c+PDCA-1+ pDC) in spleen. Numbers next 
to gate depict percentages of parent population. Representative results are shown. Three 
mice per group were used. 
 
The very low recovery of CDP progeny after 4 weeks indicates either a low 
engraftment and/or developmental potential of the injected CDP, or a short 
lifespan of CDP and their progeny. The main CDP progeny after 4 weeks were 
B cells, which have a remarkably longer half-life (5-6 weeks) than myeloid 
cells, such as monocytes and DC that have a half-life of days and are 
continuously replaced by blood-borne precursors (Fulcher and Basten, 1997; 
Merad and Manz, 2009; Geissmann et al., 2010). Therefore, to ensure that the 
full potential of CDP-derived cells is detected in vivo, I analysed the 
differentiation potential of MPP and CDP in vivo 10 days after transplantation. 
Both MPP and CDP gave rise to DC in vivo after 10 days (Fig 3.15). 
Importantly, they were able to generate all lymphoid tissue DC subsets: pDC, 
CD8α+ cDC and CD11b+ cDC.  In spleen, over 90% of CDP progeny was DC, 
whereas in bone marrow percentage of CDP-derived DC remained at or under 
4% (Fig. 3.15B and D). The rest of CDP progeny was B cells (Fig. 3.16B), 
both in bone marrow and in spleen. Whereas MPP again showed multilineage 
potential and gave rise to DC, myeloid (CD11b+) cells and B cells (Fig. 3.15A 
and C, Fig. 3.16A) CDP were essentially devoid of myeloid potential (Fig. 
3.16B). No T cell development could be observed, since T cells only develop 
3-4 weeks after transplantation (Fig. 3.16A and B, see Fig. 3.13B). 
The B cell potential of MPP and CDP was also observed in B cell cultures 
(OP9 co-culture with IL-7 and Flt3L), where both MPP and CDP were able to 
produce B220+CD19+ B cells (Fig. 3.16C and D). Noteworthy however, CDP 
went through a selection phase in OP9 co-cultures with an initial phase of cell 
death and high proliferative potential of the surviving cells. This was not 
observed with MPP, suggesting that CDP do not possess a clonal potential for 
B cell differentiation. 
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Figure 3.15. In vivo DC differentiation potential of MPP and CDP. 
In vitro amplified progenitors were generated from CD45.2+ bone marrow. MPP and CDP 
were sorted by FACS as Flt3-/loc-kithiCD11c- and Flt3+CD11chiM-CSFR+IL-7Rα-CD11c- 
cells, respectively, and 106 cells were used for transplantation into lethally irradiated CD45.1+ 
recipient mice along with a radio-protective dose of CD45.1+ bone marrow. Single cell 
suspensions of spleen (A and B) and bone marrow (C and D) were analysed for CD45.2+ 
donor-derived DC 10 days after transplantation. pDC were analysed as CD11c+PDCA-
1+CD11b-, CD8α+ cDC as CD11c+ PDCA-1-CD11b- and CD11bhi cDC as CD11c+ PDCA-1-
CD11b+ cells. (A and C) MPP-derived DC in spleen and bone marrow, respectively. (B and D) 
CDP-derived DC in spleen and bone marrow, respectively. Closed histogram represents 
isotype control, open histogram with solid line pDC and open histrogram with dotted line cDC. 
Representative results are shown. Three mice per group were used. 
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Figure 3.16. In vivo and in vitro B cell differentiation potential of MPP and CDP. 
In vitro amplified progenitors were generated from CD45.2+ bone marrow. MPP (A and C) 
and CDP (B and D) were sorted by FACS as Flt3-/loc-kithiCD11c- and Flt3+c-kitintM-
CSFR+IL-7Rα-CD11c- cells, respectively. (A and B) 106 sorted cells were used for 
transplantation into lethally irradiated CD45.1+ recipient mice. Single cell suspensions of 
spleen and bone marrow were analysed for CD45.2+ donor-derived CD11b-CD19+ or CD3ε-
CD19+ B cells 10 days after transplantation. (C and D) Sorted MPP (C) and CDP (D) were 
differentiated into B cells in co-cultures with OP-9 cells and IL-7 and Flt3L for 10 days. B cells 
were analysed as CD11b-B220+CD19+ cells. Closed histogram represents isotype control, 
open histogram staining with antibody. Representative data of three independent experiments 
are shown. Three mice per group were used. 
 
The limited differentiation potential of CDP in colony formation assays and in 
vivo indicated that CDP is positioned downstream of MPP. To investigate the 
population hierarchy between MPP and CDP, FACS sorted populations were 
cultured under growth conditions (Flt3L, SCF, hyper-IL-6 and IGF-1). Cells 
were counted and analysed by flow cytometry for MPP/CDP markers at days 
2, 5 and 8 after sorting. Interestingly, only MPP were able to extensively 
proliferate and reproduce both MPP and CDP (Fig. 3.17A and C). CDP 
showed a significantly lower proliferation capacity and even under growth 
conditions differentiated into CD11c+MHCII+ DC (Fig. 3.17A, B and C, and 
data not shown). Notably, there was no differentiation into CD11c+MHCII+ DC 
from MPP by day 8. 
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Figure 3.17. Population hierarchy from MPP to CDP. 
FACS sorted MPP and CDP populations were cultured further under amplification conditions 
(Flt3L, SCF, hyper-IL-6 and IGF-1) and analysed at days 2, 5 and 8 after sorting. (A) 
MPP/CDP development was monitored by staining cells for c-kit and Flt3. (B) Spontaneous 
DC differentiation was analysed by measuring CD11c expression. (C) Cumulative cell 
numbers were determined at regular time intervals and are depicted. Representative data 
from two independent experiments are shown. 
 
In summary, the differentiation potential in vivo and in vitro, and the evident 
hierarchy between MPP and CDP supports the hypothesis that the 
multilineage potential resides in the MPP population whereas CDP have a 
more limited differentiation potential. 
 
 3.3.3 CDP Readily Differentiate into Multiple DC Subsets in vitro 
Although giving valuable information on the in vivo DC differentiation potential, 
the cell transfer assay into lethally irradiated recipients has its drawbacks. For 
one, irradiation is considered to result in a whole body inflammation. Serum 
levels of cytokines, including potent DC cytokines, have been reported to be 
elevated in irradiated animals (Tsuboi et al., 2008), and normally recipient 
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mice are only analysed after a minimum of 4 weeks recovery time to reach 
steady state conditions. Because of the short lifespan of CDP and its progeny 
(DC), recipient mice had to be analysed already after 10 days, i.e. in a non-
homeostatic environment. 
Therefore, to gain insight into DC differentiation potential in a more controlled 
system, DC differentiation and kinetics of MPP and CDP were determined in 
vitro in response to single DC-poietins. MPP and CDP were FACS sorted and 
DC differentiation was induced by addition of Flt3L, M-CSF or GM-CSF to 
generate DC and monocytes/macrophages. Both MPP and CDP were able to 
give rise to pDC and cDC when cultured with Flt3L or M-CSF, including CD8α-
like DC with Flt3L (Fig. 3.18A and B, and data not shown). In addition, under 
GM-CSF conditions both progenitors gave rise to CD11chiMHCII+ 
inflammatory DC (Fig. 3.18C). 
CDP differentiated into CD11c+ DC with considerably faster kinetics reaching 
70-90% CD11c+ cells already after 3 days in comparison to 10-30% in MPP 
cultures (Fig. 3.18D). Consistent with the fast differentiation kinetics, the 
proliferation capacity of CDP was limited and CDP cultures showed a limited 
initial phase of proliferation within the first days and cell numbers rapidly 
declined upon differentiation (Fig. 3.18E). On the contrary, MPP showed a 
higher proliferative potential in response to Flt3L and GM-CSF than CDP and 
required a longer time to fully differentiate into DC (Fig. 3.18D and E). 
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Figure 3.18. DC differentiation from MPP and CDP in vitro. 
FACS sorted CDP and MPP were cultured with Flt3L, GM-CSF or M-CSF to generate DC 
subsets and analysed by flow cytometry (A-C, respectively). (A) CD11c+ cells were 
subdivided into pDC and cDC (CD11b-B220+ and CD11b+B220-, respectively) at day 8 of 
differentiation culture with Flt3L. (B) pDC (CD11b-Siglec-H+) obtained with M-CSF at day 5 of 
differentiation culture. Siglec-H+ cells were also CD11c+ and B220+ (data not shown). (C) 
CD11c+MHCIIhi DC obtained with GM-CSF at day 5 of differentiation culture.  (D) 
Differentiation of MPP and CDP into CD11c+ cells in Flt3L, GM-CSF or M-CSF cultures was 
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followed in time as indicated. (E) Proliferation of MPP and CDP in Flt3L, GM-CSF or M-CSF 
cultures was followed in time and is presented as fold change relative to the number of cells 
seeded. 
 
Differentiation into monocytes/macrophages with M-CSF was more efficient 
for MPP than CDP (70.1% vs. 45.7% CD11b+CD115+ cells) (Fig. 3.19). This 
remaining monocyte/macrophage potential of CDP is consistent with the data 
from the in vivo CDP (Onai et al., 2007b; Naik et al., 2007) and is more limited 
than that of MPP. 
 
 
Figure 3.19. Differentiation of MPP and CDP into monocytes in vitro. 
FACS sorted CDP and MPP were cultured with M-CSF and the generated cells (both 
adherent and suspension cells) were analysed by flow cytometry for monocyte differentiation 
at day 8. CD11b+CD115+ cells were further characterised for F4/80 and Gr-1 expression. 
 
Taken together, both MPP and CDP have the full potential to generate all DC 
subsets in vitro. CDP are considerably faster in DC differentiation and have a 
limited proliferation capacity, which is consistent with their position in 
differentiation hierarchy downstream of MPP. 
 
3.4 Molecular Mechanisms Underlying the DC-Priming of CDP 
3.4.1 CDP Have a DC-Primed Transcription Profile 
To obtain further insight into the DC priming of CDP, genome-wide gene 
expression analysis was performed (in collaboration with Qiong Lin, Institute 
for Biomedical Engineering – Cell Biology, RWTH Aachen). Therefore, MPP 
and CDP were FACS sorted as in Fig. 3.12A. The expression profiles of MPP 
and CDP were compared to those of in vitro generated and FACS sorted pDC 
and cDC. I concentrated the analysis on 1019 probe sets (coding for 775 
genes) that were more than 2-fold differentially expressed between MPP and 
CDP. (Full list of genes is shown in Supplementary Table 1.) The transcripts 
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were subjected to hierarchical cluster analysis and data were displayed in a 
heatmap format (Fig. 3.20A). 
Hierarchical cluster analysis revealed distinct gene clusters I-VII (Fig. 3.20A), 
of which clusters I, II and IV demonstrated the activation of a DC-like 
expression profile in CDP. Conversely, cluster VI exhibited ʻMPP genesʼ, the 
expression of which was repressed in CDP and differentiated cells. Notably, 
CDP clustered together with the DC samples according to the expression 
pattern, indicating a close similarity between CDP and DC. 
 
 
Figure 3.20. CDP have a DC-primed gene expression profile. 
MPP and CDP were obtained by FACS sorting from bone marrow cultures with Flt3L, SCF, 
hyper-IL-6 and IGF-1 (day 7). DC differentiation from amplified progenitors was induced with 
Flt3L at day 7. cDC and pDC were sorted from Flt3L cultures by FACS at differentiation day 6 
as CD11c+CD11b+ and CD11c+CD11b-PDCA-1+B220+ cells, respectively. Total RNA was 
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extracted and subjected to DNA microarray analysis (A) and semi-quantitative RT-PCR 
analysis (B). (A) Gene expression data of the 1019 probe sets differentially regulated between 
MPP and CDP depicted in a heatmap format. Clusters I, II and IV containing DC genes and 
cluster VI containing MPP genes are marked with black boxes. (B) Representative genes from 
clusters in (A) were subjected to semi-quantitative RT-PCR analysis. C, negative control. 
 
Table 3.2. Genes differentially regulated between MPP and CDP. 
Cluster Gene Function Gene Name 
Membrane protein Flt3, Il10Ra, Ccr5 
Transcription Factor Irf5, Irf8 
I Pan-DC 
Other Ctsh, Ctss, Casp6 
Membrane protein Tlr7, Cd28, Cd38 II pDC 
Transcription Factor Tcf4, Notch1 
III MPP&DC Membrane protein Igf1r 
Membrane protein Cx3cr1, Tlr2, Fcgr1 
Transcription Factor Id2 
IV cDC 
Other Lgmn, Ctsc 
Membrane protein Csf1r V CDP 
Transcription Factor Id3 
Membrane protein Ncam1, Trfr2, Prom1, Itga6, 
Cd34 
VI MPP 
Transcription Factor Gata2, Cebpa, Nfe2, Tal1, 
Gfi1 
VII MPP&cDC Membrane protein Kit 
 
Selected genes of clusters shown in Fig. 3.20A are depicted. 
 
Cluster I contains so-called pan-DC genes, such as Flt3 and IRF-8 (Fig. 3.20A 
and Table 3.2), both essential for cDC and pDC development. Flt3 and IRF-8 
mRNA levels were confirmed with RT-PCR analysis and found to be 
consistent with the array data (Fig. 3.20B). Cluster I also includes other 
cytokine and chemokine receptors, such as IL10Rα and CCR5, and the 
transcription factor IRF-5. CCR5 and IRF-5 are involved in DC function upon 
infection (Takaoka et al., 2005) whereas IL10Rα mediates the 
immunosuppressive signal of IL-10 to DC (Moore et al., 2001). Other genes 
coding for proteins related to DC function include the cathepsin and caspase 
genes (Ctsh, Ctss and Casp6), of which especially cathepsin S (encoded by 
Ctss) is important for MHC class II-associated antigen presentation 
(Nakagawa et al., 1999; Shi et al., 1999; Driessen et al., 1999). 
Cluster II identifies pDC genes, including toll-like receptor TLR7 and the 
transcription factor Tcf4 (E2-2) (Fig. 3.20A and Table 3.2). TLR7 and Tcf4/E2-
2 also showed highest expression in pDC by RT-PCR (Fig. 3.20B), and both 
genes were upregulated from MPP to CDP. Lymphoid-related genes such as 
the transcription factor Notch1, described to be expressed in murine bone 
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marrow pDC (Pelayo et al., 2005), and the surface markers CD28 and CD38 
are also found in the pDC cluster. 
Cluster IV comprises cDC genes with already high expression in CDP, 
including ʻmyeloid genesʼ like TLR2 and FcγR1 (Fig. 3.20A and Table 3.2). 
The chemokine receptor CX3CR1, which is often used to characterise CDP 
(Fig 3.12, (Waskow et al., 2008; Auffray et al., 2009a; Liu et al., 2009), was 
also highly expressed in cDC. High expression of the transcription factor Id2 in 
CDP and cDC is consistent with the restricted potential of CDP and the 
requirement of Id2 for CD8α+ cDC development (Fig. 3.20A and B) (Hacker et 
al., 2003). Cluster IV also includes genes encoding for functional proteins 
such as Lgmn and Ctsc, of which legumain (encoded by Lgmn) has been 
reported to be involved in processing antigens for MHC class II presentation 
(Manoury et al., 1998). 
Cluster V identifies CDP specific genes, which include CSF-1R, encoding the 
M-CSF receptor, and the transcription factor Id3 (Fig. 3.20A and B, Table 3.2). 
CDP are characterised as M-CSFR+ cells and CSF-1R expression indeed 
peaks in CDP (Fig 3.12, Fig. 3.20A and B). Id3, similarly to Id2, presumably 
contributes to the restricted developmental potential of CDP (Kee, 2009). 
Cluster VI consists of early hematopoietic stem cell genes. Importantly, 
several transcription factors related to stem cell proliferation and self-renewal, 
like GATA-2, CEBPα, NFE2, Tal1, and Gfi1 (Briegel et al., 1993; Tsai et al., 
1994; Wilson et al., 2009; Zeng et al., 2004), were highly expressed in MPP 
and downregulated in CDP and DC, consistent with the restricted proliferation 
and developmental potential of CDP and differentiated DC (Fig. 3.20A and 
Table 3.2). A number of stem cell-related surface antigens were expressed on 
mRNA level on MPP, including NCAM1, Trfr2, Prom1, Itga6 (CD49f), and 
CD34 (Ivanova et al., 2002; Ramalho-Santos et al., 2002; Mansson et al., 
2007). The array data was found to be consistent with RT-PCR analysis for 
GATA-2 and CEBPα expression (Fig. 3.20B). Interestingly, the SCF receptor 
c-kit, used to characterise MPP in flow cytometry (Fig. 3.12), clustered 
separately in a minor cluster of genes prominent in MPP and cDC (Cluster VII, 
Fig. 3.20A and B, Table 3.2). High c-kit expression on cDC is consistent with 
previous reports (Krishnamoorthy et al., 2008). 
Taken together, genes important to DC differentiation are upregulated from 
MPP to CDP and even further enhanced in DC. Importantly, CDP express 
both cDC and pDC specific genes, consistent with their capacity to 
differentiate into both DC subsets. Simultaneously, expression of 
RESULTS 57 
 
proliferation/multipotency-associated genes declines upon CDP differentiation 
from MPP. Thus, the gene expression analysis provides further support for the 
early, multipotent character of MPP and the DC-restricted/primed character of 
CDP. 
 
3.4.2 The Transcription Profile of Amplified CDP Correlates with the in vivo 
CDP 
The amplified CDP recapitulate the surface marker profile and function of the 
in vivo bone marrow CDP. They also clearly show a DC-primed expression 
profile. To analyse how similar the two CDP populations are on global 
transcription level and, hence, how relevant the DC-primed expression profile 
of amplified CDP is, I compared the expression profiles of in vitro amplified 
and freshly isolated in vivo CDP. To isolate in vivo CDP, bone marrow of eight 
to ten mice was pooled and in vivo CDP were FACS sorted as lineage 
negative, Flt3+c-KitintM-CSFR+IL-7Rα- cells and genome-wide gene 
expression was analysed by DNA microarray (in collaboration with Qiong Lin, 
Institute for Biomedical Engineering – Cell Biology, RWTH Aachen). Principal 
component analysis (PCA) depicts the similarity/differences of samples based 
on principal components that account for as much of the variance in the data 
as possible. In case of DNA microarray data, individual genes present on the 
microarray chips are considered as variables. Principal components (PC) 1 
and PC2 grouped the progenitors (MPP, in vitro CDP and in vivo CDP) 
separate from the differentiated DC (Fig. 3.21A). PC2 also displayed the 
difference between in vitro generated cells and in vivo CDP. PC1 and PC3 
clustered both CDP populations very close together (Fig. 3.21B). The 
progenitors still grouped together, clearly separated from the differentiated 
cells. PC1 and PC3 contain 62.2% of the information on the microarrays and 
demonstrate that amplified and in vivo CDP are similar on global gene 
expression level. 
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Figure 3.21. Principal component analysis of in vivo CDP and in vitro generated MPP, 
CDP and DC subsets. 
Principal component analysis (PCA) of in vivo CDPs and in vitro generated MPP, CDP, cDC 
and pDC. Each symbol represents a microarray data set; blue triangles, MPP; orange 
squares, in vitro CDP; green diamonds, in vivo CDP; red dots, cDC; purple triangles, pDC. (A) 
The two principal components PC1 and PC2 show variances of 46.3% and 22.2%, 
respectively. (B) PC1 and PC3 show variances of 46.3% and 15.9%, respectively. 
 
Finally, the correlation of expression for the genes in Fig. 3.20A showing the 
DC-priming of CDP was tested between the in vitro amplified cells and in vivo 
CDP. The data are depicted in a heatmap format (Fig. 3.22) that demonstrates 
high correlation between the CDP samples and clusters them together based 
on the expression pattern for the selected genes. 
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Figure 3.22. Correlation analysis of gene expression between amplified MPP, CDP and 
DC and in vivo CDP. 
Correlation matrix of in vivo CDP and in vitro generated MPP, CDP, pDC, cDC is depicted in a 
heatmap format. Pearson correlation coefficients of sample pairs were calculated for 
differentially expressed genes between MPP and CDP as in Fig. 3.20A. Red, high correlation; 
blue, low correlation. 
 
Taken together, the gene expression analysis demonstrates a close 
correlation on molecular level for in vitro and in vivo CDP. Hence, the in vitro 
amplified CDP provide an important and relevant model system that 
reproduces defined stage-specific cells in culture. The amplified CDP are 
readily manipulated with e.g. retrovirus and lentivirus (data not shown) and are 
easily amplified to abundant numbers. This allows the study of single factors, 
such as cytokines and transcription factors, and their involvement in DC 
subset specification at defined differentiation stages. 
 
3.5 TGF-β1 Signalling in DC Development 
Studies in human and mice have demonstrated that TGF-β1 signalling is 
critical for LC differentiation both in vivo and in vitro (Borkowski et al., 1996; 
Strobl et al., 1996; Strobl et al., 1997). The transcription factors Id2 and Runx3 
have been identified as crucial mediators of TGF-β1 signalling in LC 
development, being some of the first identified pathways that couple cytokine 
signalling with transcription factors in determining DC differentiation (Hacker et 
al., 2003; Fainaru et al., 2004). Moreover, it has been shown that in addition to 
being devoid of LC, Id2 deficient mice also lack CD8α+ cDC and have 
increased frequency of pDC (Hacker et al., 2003). Yet the role of TGF-β1 
signalling in the development of other DC subsets remains unknown. 
Interestingly, previous studies demonstrated that Id2 expression is 
upregulated during human DC differentiation and Id2 expression is positively 
regulated by TGF-β1 in human DC progenitors (Hacker et al., 2003). Further 
TGF-β1 target genes in DC were investigated here, extending on the analysis 
of human DC and taking advantage of the mouse system described above 
that generates MPP, CDP and DC subsets in vitro. 
 
3.5.1 TGF-β1 Induces IRF-8 Expression in Human DCs 
Hematopoietic progenitors were amplified from CD34+ cord blood cells and 
their differentiation into DC was induced by GM-CSF and IL-4 (Fig. 3.23, Ju 
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and Zenke, 2003). DC were treated with TGF-β1 for different periods of time 
or left untreated and the samples were subjected to genome-wide gene 
expression analysis. The analysis identified 147 transcription factors regulated 
more than 2-fold by TGF-β1 (Fig. 3.24A, in collaboration with X-S Ju, Institute 
for Biomedical Engineering – Cell Biology, RWTH Aachen, Ju et al., 2007). 
These included several of the IRF transcription factor family members (Fig. 
3.24A and B), a number of which have been implicated in DC development or 
function (Gabriele and Ozato, 2007). IRF-8 was particularly interesting, since it 
is known to be involved in the development of several DC subsets: IRF-8 
deficient mice lack pDC and CD8α+ DC, have decreased frequency of LC and, 
in addition, DC function in these mice is severely impaired (Schiavoni et al., 
2002; Schiavoni et al., 2004). To confirm that IRF-8 regulation is dependent on 
TGF-β1 signalling, DC were treated with a specific inhibitor for type I TGF-β1 
receptor (ALK-5); SB431542. SB431542 treatment completely blocked TGF-
β1-induced Smad2/3 phosphorylation and, hence, TGF-β1 signalling in human 
DC (Fig. 3.25A). Correspondingly, TGF-β1 induced IRF-8 expression was 
completely abolished in SB431542 treated DC (Fig. 3.25B). Smad7 
expression was used as a control, as its expression is induced by TGF-β1 
signalling to generate a negative feedback loop (Nakao et al., 1997). The 
upregulation of IRF-8 by TGF-β1 was also confirmed on protein level by 
Western immunoblotting (Fig. 3.25C). 
 
 
Figure 3.23. Schematic presentation of human DC culture. 
CD34+ progenitors are isolated from cord blood by immunomagnetic bead selection. The 
progenitors are amplified with a cytokine cocktail of Flt3L, SCF, IGF-1 and TPO for 7 days. 
DC differentiation is induced by GM-CSF and IL-4. DC at day 6 or 7 of differentiation were 
treated with TGF-β1 for different periods of time. Adapted from B. Panzenböck, PhD Thesis, 
Vienna, Austria. 
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Figure 3.24. TGF-β1 regulates the expression of 147 transcription factors in human DC. 
(A) DC at day 6 of differentiation were treated with TGF-β1 for 0, 4, 16 and 36 hours. 
Hierarchical cluster analysis of transcription factors with more than twofold change in 
expression levels is depicted in a heatmap. Each gene is represented by a single row of 
coloured boxes. Green, transcription levels below median; black, transcription levels equal to 
median; red, transcription levels higher than median. Clusters I and II show upregulated 
genes, downregulated genes are shown in clusters III and IV. (B) Expression of IRF family 
members and Langerin in human HPC and DC treated with TGF-β1 for 0, 4, 16 and 36 hours 
was analysed by RT-PCR. GAPDH expression was used as control. Adapted from Ju et al., 
2007. 
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Figure 3.25. TGF-β1 upregulates IRF-8 expression in human DC. 
(A) Immunoblot analysis of phospho-Smad2/3 protein expression in human DC (day 6) 
treated with TGF-β1 (10 ng/ml) for 30 min. To block TGF-β1 signalling, cells were pre-
incubated with SB431542 (5  µM) for 2 h before TGF-β1 treatment. (B) DC (day 6) were 
treated with TGF-β1 (10 ng/ml) for 2, 4 and 8 h or left untreated. TGF-β1 signalling was 
blocked with pre-incubation with SB431542 (5  µM) for 2 h before TGF-β1 treatment. 
Expression for IRF-8, Smad7 and GAPDH was analysed by RT-PCR. (C) Immunoblot 
analysis of IRF-8 protein expression in human HPC, DC (day 6) and DC treated with TGF-β1 
for additional 24 h and 48 h. Actin expression is shown as control. 
 
3.5.2 TGF-β1 Accelerates DC Development and Directs Subset Specification 
Towards cDC 
TGF-β1 induces Id2 and IRF-8 expression in human DC and enhances LC 
development/differentiation in human DC cultures (Hacker et al., 2003; Ju et 
al., 2007; Strobl et al., 1996; Strobl et al., 1997). Both Id2 and IRF-8 are 
known to be essential for DC subset specification (Hacker et al., 2003; 
Schiavoni et al., 2002; Schiavoni et al., 2004). However, GM-CSF induced 
human DC cultures do not support the development of multiple DC subsets, 
and the consecutive development stages from MPP via committed DC 
progenitors to DC are more poorly characterised in human than in mouse. On 
the contrary, the mouse culture system described above (Chapters 3.2 to 3.4) 
provides an excellent means to decipher molecular events in response to 
single cytokines, like TGF-β1, in CDP and the consequences thereof. 
Therefore, in order to gain more insight into the impact of TGF-β1 signalling on 
DC development and subset specification, I employed the mouse CDP culture. 
First, I confirmed the upregulation of the TGF-β1 target genes Id2 and IRF-8 in 
mouse DC. Therefore, bone marrow progenitors were amplified with Flt3L, 
SCF, hyper-IL-6 and IGF-1 and their differentiation into DC was induced by 
Flt3L. Amplified progenitors and DC at different stages of their development 
were treated with TGF-β1 and gene expression was analysed by RT-PCR 
(Fig. 3.26). TGF-β1 upregulated Id2, IRF-8 and Langerin expression in mouse 
progenitors and early DC (Fig. 3.26A and B). Interestingly, similar to human 
DC, these TGF-β1 target genes were also upregulated during DC 
differentiation without addition of exogenous TGF-β1 (Fig. 3.26A and C), 
suggesting that TGF-β1 accelerates DC differentiation. 
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Figure 3.26. TGF-β1 induces Id2, IRF-8 and Langerin expression in mouse DC 
progenitors. 
Bone marrow progenitors were amplified with Flt3L, SCF, hyper-IL-6 and IGF-1 for 7 days. DC 
differentiation was induced with Flt3L. Progenitors (day 0) and DC cultures (days 3, 6 and 10) 
were treated with TGF-β1 (10 ng/ml) for 2, 4, 8, 16 and 24 h or left untreated. (A) Expression 
for Id2, IRF-8, Langerin, Smad7 and actin was analysed by RT-PCR. (B-C) Expression for 
Id2, IRF-8, Langerin and Smad7 was quantified and normalised against actin and is depicted 
in a heatmap format. (B) Id2, IRF-8, Langerin and Smad7 expression in amplified progenitors 
treated with TGF-β1. (C) Id2, IRF-8 and Langerin expression during DC differentiation without 
addition of exogenous TGF-β1. 
 
Next, CDP were obtained by in vitro culture, FACS sorted and treated with 
TGF-β1 for 4, 8, 12 and 24 hours for genome-wide gene expression analysis 
(in collaboration with Qiong Lin, Institute for Biomedical Engineering – Cell 
Biology, RWTH Aachen). 3758 genes were regulated more than 2-fold by 
TGF-β1 and were further subjected to cluster analysis. (Full list of genes is 
shown in Supplementary Table 2.) The profiling revealed clusters of up- and 
downregulated genes that contained known TGF-β1 target genes, such as 
Smad7, Id2 and IRF-4 (Fig. 3.27) (Nakao et al., 1997; Hacker et al., 2003; Ju 
et al., 2007). 
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Figure 3.27. Clustering of TGF-β1 regulated genes in CDP. 
3758 genes were regulated more than 2-fold by TGF-β1 and were analyzed by Fuzzy c-
means clustering. Clusters 2 and 6 display continuously upregulated genes and cluster 3 
upregulated genes with delayed kinetics. Clusters 1, 4 and 5 show downregulated genes. 
Number of genes in each cluster and representative genes are depicted. 
 
To investigate the impact of TGF-β1 on a global level, the TGF-β1 treated and 
untreated CDP samples were subjected to principal component analysis (in 
collaboration with Qiong Lin, Institute for Biomedical Engineering – Cell 
Biology, RWTH Aachen). The analysis positioned TGF-β1 treated CDP 
between untreated CDP and DC subsets, cDC and pDC, indicating that TGF-
β1 promotes DC differentiation (Fig. 3.28A). This was further supported when 
the TGF-β1 regulated genes were subjected to GO (GO; 
www.geneontology.org) overrepresentation analysis (in collaboration with 
Qiong Lin, Institute for Biomedical Engineering – Cell Biology, RWTH 
Aachen): TGF-β1 induced genes were found in GO categories related to 
immune cell activation and differentiation, antigen presentation and signal 
transduction (Table 3.3). On the contrary, TGF-β1 downregulated genes were 
involved in nucleic acid and amino acid metabolism and cell cycle control 
(Table 3.3), which also relates to the DC differentiation promoting activity of 
TGF-β1. (Full list of GO terms with genes in each category is shown in 
Supplementary Table 3.) 
To further extend this observation, I generated DC with Flt3L in the presence 
and absence of TGF-β1 and analysed DC development by flow cytometry. 
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Strikingly, TGF-β1 compromised pDC development whereas cDC 
differentiation remained unaffected (Fig. 3.28B). TGF-β1 inhibits B cell 
development by inducing apoptosis in B cell progenitors (Kee et al., 2001). 
Similarly, TGF-β1 induced apoptosis in CDP cultured with Flt3L (Fig. 3.28C 
and D). 
 
 
Figure 3.28. TGF-β1 accelerates DC differentiation and directs subset specification 
towards cDC. 
(A) PCA of TGF-β1 treated (24 h) and untreated (0 h) CDP, and of cDC and pDC based on 
the expression of genes differentially regulated more than 2-fold by TGF-β1 (3758 genes). 
The two principal components PC1 and PC3 showed variances of 45.1% and 18.4%, 
respectively. (B) Bone marrow progenitors were amplified with Flt3L, SCF, hyper-IL-6 and 
IGF-1 for 7 days. DC differentiation was induced with Flt3L in the presence or absence of 
TGF-β1 (3 ng/ml). Cultures were analysed for pDC (CD11c+CD11b-B220+) and cDC 
(CD11c+CD11b+B220-) subsets at day 10 of differentiation. Representative data from at least 
three independent experiments are shown. (C and D) MPP and CDP were obtained by FACS 
sorting at day 7 as Flt3-/loc-kithiCD11c- and Flt3+c-kitintM-CSFR+CD11c-IL-7Rα- cells, 
respectively, and DC differentiation was induced with Flt3L. 16 h later, cultures were treated 
with TGF-β1 (3 ng/ml) for 48 h. Apoptosis was analyzed with Annexin V and PI staining and 
viable cells (PI-) and apoptotic cells (Annexin V+ PI-) are depicted (C and D, respectively). 
Error bars represent SD from mean (n=4). Data shown are from two independent 
experiments. 
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Table 3.3. GO terms among the genes up- and downregulated by TGF-β1 in CDP. 
Upregulated genes 
GO ID Term Count P-value 
GO:0002504 antigen processing and 
presentation of peptide or 
polysaccharide antigen via 
MHC class II 
8 1.45E-03 
GO:0006468 protein amino acid 
phosphorylation 
74 1.45E-03 
GO:0051251 positive regulation of 
lymphocyte activation 
19 1.45E-03 
GO:0007242 intracellular signalling cascade 100 1.45E-03 
GO:0002520 immune system development 44 1.48E-03 
GO:0002694 regulation of leukocyte 
activation 
24 1.57E-03 
GO:0050867 positive regulation of cell 
activation 
19 1.57E-03 
GO:0045619 regulation of lymphocyte 
differentiation 
14 1.91E-03 
GO:0007165 signal transduction 117 2.32E-03 
GO:0050863 regulation of T cell activation 19 3.20E-03 
 
Downregulated genes 
GO ID Term Count P-value 
GO:0006364 rRNA processing 31 1.62E-16 
GO:0006396 RNA processing 77 1.62E-16 
GO:0034660 ncRNA metabolic process 31 1.75E-16 
GO:0042254 ribosome biogenesis 16 2.56E-09 
GO:0044085 cellular component biogenesis 73 5.88E-09 
GO:0006260 DNA replication 31 5.17E-08 
GO:0008033 tRNA processing 19 2.35E-06 
GO:0006519 cellular amino acid and 
derivative metabolic process 
44 2.75E-06 
GO:0044106 cellular amine metabolic 
process 
31 3.67E-05 
GO:0051028 mRNA transport 15 1.50E-04 
 
Genes regulated more than 2-fold by TGF-β1 in CDP between 0 h and 24 h were subjected to 
GO overrepresentation analysis. 10 GO categories (biological process) with the lowest P-
values for up- and downregulated genes are depicted. 
 
Given the instructive role of transcription factors and cytokine-driven signalling 
in DC differentiation, I further focused on transcription factors and surface 
molecules regulated by TGF-β1. TGF-β1 induced pan-DC genes, such as 
Flt3, CD11c/Itgax and IL10Rα (Table 3.4, see also Table 3.2). Moreover, TGF-
β1 induced a cDC-like transcription profile in CDP by upregulating the 
expression of Id2, members of NF-κB signaling pathway (Nfkb1, Nfkb2, 
Nfkbie, relB, Rel), MHC class II and costimulatory molecules, such as H2-
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DMa, H2-DMb2, CD74 (MHC-II invariant chain), CD40 and CD80 (Table 3.4). 
The induction of a cDC-like transcription profile in TGF-β1 treated CDP was 
also observed by hierarchical cluster analysis (Fig. 3.29A). Interestingly, 
expression of pDC affiliated genes, such as CD28, CD38, TLR7 and Notch1 
was downregulated by TGF-β1 similar to the MPP related genes Myb, Myc 
and Gfi1 (Table 3.4, see also Table 3.2). These results were further supported 
by RT-PCR analysis (Fig. 3.29B). 
 
Table 3.4. TGF-β1 regulated genes in CDP. 
TGF-β1 effect Gene Function Gene Name 
Membrane protein Cd5, Cd11c/Itgax, Cd40, 
Cd74/MHC-II invariant 
chain, Cd80, Ccr1, Ccr7, 
Csf1r, Flt3, Il10ra, Il13ra1, 
MHC-II/H2-DMa, MHC-
II/H2-DMb2 
Transcription Factor Bhlhe40/Dec1,Ciita, Id2, 
Irf1, Irf4, Irf5, Irf9, Klf4, Klf6, 
Klf7, Nfkb1, Nfkb2, Nfkbie, 
Notch2, Rel, relB, Runx3, 
Ski, Skil, Vdr 
Upregulation 
Other Card6, Card11, Ctss, Lyst 
Membrane protein Cd28, Cd38, Tlr7 Downregulation 
Transcription Factor Cebpb, Gfi1, Id1, Id3, Klf2, 
Klf16, Myb, Myc, Notch1 
 
Selected genes regulated more than 2-fold by TGF-β1 are depicted. 
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Figure 3.29. Transcription factors involved in TGF-β1 signalling and DC development. 
CDP were obtained from bone marrow cultures by FACS sorting as Flt3+c-kitintM-CSFR+IL-
7Rα-CD11c- cells and treated with TGF-β1 (10 ng/ml) for various periods of time (4, 8, 12 and 
24 h) or left untreated as indicated. (A) Samples were subjected to DNA microarray analysis 
(GEO accession number GSE22432) and gene array data of transcription factors involved in 
TGF-β1 signalling and DC development were analysed by hierarchical clustering and are 
depicted in a heatmap format. Genes that are highly induced upon TGF-β1 treatment after 
24h and abundantly expressed in cDC are indicated (box). (B) RT-PCR analysis of selected 
genes shown in (A). 
 
Taken together, TGF-β1 accelerates DC differentiation within 24 h by inducing 
a DC affiliated transcription profile. In addition, TGF-β1 functions on the 
bifurcation point of DC subset specification and promotes cDC differentiation 
at the expense of pDC development. 
Interestingly, one TGF-β1 induced gene was Id2 that has been previously 
indicated in inhibiting pDC differentiation: ectopic Id2 and Id3 overexpression 
blocks pDC differentiation from human CD34+ cells, whereas cDC 
development remains unaffected (Spits et al., 2000). Id2 deficient mice also 
possess slightly increased numbers of pDC (Hacker et al., 2003). To test 
whether the TGF-β1 induced apoptosis in MPP and CDP cultures and the 
inhibition of pDC development depends on upregulation of Id2, DC 
differentiation from Id2 wildtype and Id2 deficient bone marrow was induced 
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with Flt3L in the presence and absence of TGF-β1. Untreated Id2-/- cultures 
had slightly elevated frequencies of pDC, in line with the published in vivo data 
(Fig. 3.30A) (Hacker et al., 2003). However, pDC development was inhibited in 
Id2-/- cultures in the presence of TGF-β1, similar to wildtype cultures (Fig. 
3.30B). The Id2-independent inhibition of pDC development indicates that Id2 
alone is not the sole factor that inhibits pDC development in response to TGF-
β1. Alternatively, other mechanisms, such as other Id family members or 
repressive HLH factors (e.g. Bhlhe40/Stra13/Dec1), compensate for the loss 
of Id2 in Id2 deficient mice. 
 
 
Figure 3.30. TGF-β1 inhibits pDC development in Id2-/- cultures. 
DC subsets were generated from bone marrow with a one-step Flt3L culture system. DC 
subsets were analysed by flow cytometry at day 10 of differentiation. (A) cDC and pDC in 
Flt3L cultures obtained from the bone marrow of wildtype (Id2+/+) and Id2 deficient (Id2-/-) 
mice. Cells were pre-gated on CD11c+ cells. cDC were analysed as CD11b+B220- cells, and 
pDC as CD11b-B220+ cells. Numbers next to gates depict percentages of CD11c+ cells. (B) 
Flt3L cultures obtained from Id2 deficient mice were treated with 3 ng/ml TGF-β1 from day 0 
or day 5 until day 10, or left untreated. Numbers next to gates depict percentages of parent 
population. 
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3.6 E2A/Id Antagonism in DC Development 
Id proteins are HLH factors that lack the adjacent basic region required for 
DNA binding. They suppress activating HLH transcription factors by binding 
them and thereby inhibiting their DNA binding (Kee, 2009) (see below Fig. 
4.1). Alternatively, transcription by activating HLH factors is inhibited in a 
DNA-dependent fashion by repressive HLH factors, such as 
Bhlhe40/Stra13/Dec1, that occupy the E-box DNA elements and thereby 
inhibit DNA binding of activating factors (St-Pierre et al., 2002) (see below Fig. 
4.1). TGF-β1 treatment has very similar effects on DC cultures and B cell 
cultures and Id2 and Id3 overexpression inhibits both pDC and B cell 
development. E2A is a HLH factor that is essential for B cell development 
(Kee, 2009). Therefore, I investigated the role of E2A in DC development. 
 
3.6.1 Impaired pDC Development from E2A Deficient Bone Marrow Cells 
E2A encodes two alternative proteins E12 and E47 that differ only in their 
DNA binding domain encoded by alternative exons 18 (Fig. 3.31). In 
conditional E2A deficient mice the deletion of E12/E47 DNA binding domains 
occurs specifically in hematopoietic cells (Kwon et al., 2008). 
 
 
Figure 3.31. Schematic presentation of the E2A knockout strategy. 
The E2A locus for generating the conditional E2A knockout mice has loxP sites upstream of 
exon 17 and downstream of exon 19. The loxP sites are indicated by red arrowheads. Upon 
Cre expression under the Vav promoter the two alternative DNA binding domains from E2A 
isoforms E12 and E47 coded by exons 18 are specifically deleted in hematopoietic cells. After 
Cre-mediated excision a non-functional E2A-GFP fusion protein is expressed. Multiple polyA-
sites downstream of the stop codon and upstream of the GFP sequence ensure that GFP is 
not expressed before the excision. Adapted from Kwon et al., 2008. 
 
Bone marrow cells from E2A deficient mice and wildtype littermate controls 
were amplified with Flt3L, SCF, hyper-IL-6 and IGF-1. DC differentiation was 
induced with Flt3L and cultures were analysed for DC subsets at different time 
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points during differentiation. DC differentiation, determined by frequency of 
CD11c+ cells, was generally delayed in E2A deficient cultures (Fig. 3.32A and 
B). More strikingly, pDC development was completely impaired from E2A 
deficient cells, whereas cDC development remained unaffected. 
 
 
Figure 3.32. pDC development from E2A deficient progenitors is impaired in vitro. 
DC were generated with two-step Flt3L culture system. DC subsets were analysed by flow 
cytometry at days 6 (A) and 8 (B) of differentiation. cDC were analysed as 
CD11c+CD11b+B220-PDCA-1- cells and pDC as CD11c+CD11b-B220+PDCA-1+ cells. 
Numbers in gates and quadrants indicate percentage of parent population. Wildtype, WT; E2A 
knockout, KO. 
 
Frequencies of DC subsets in E2A deficient mice was also investigated in vivo 
in spleen and bone marrow. In general, frequency of DC (as percentage of 
total splenocytes) was slightly increased in E2A deficient mice compared to 
wildtype controls (Fig. 3.33A), although the difference was not statistically 
significant. Interestingly, frequency of pDC was decreased in E2A deficient 
mice in bone marrow whereas there was no difference in pDC frequencies in 
spleens of wildtype and E2A deficient mice (Fig. 3.33B and C). 
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Figure 3.33. E2A deficient mice have decreased pDC frequency in bone marrow. 
(A) Frequency of total DC as CD11c+ cells in spleen of wild type (WT) and E2A deficient (KO) 
mice. (B) Bone marrow pDC in wild type (WT) and E2A deficient (KO) mice were analysed by 
flow cytometry as CD11b-B220+PDCA-1+ cells. Cells were also positive for CD11c and 
SiglecH expression. Representative staining is shown. Numbers in gates indicate percentage 
of parent population. (C) Frequency of pDC in bone marrow and spleen of wild type (WT) and 
E2A deficient (KO) mice. Frequencies depict percentages of total cell number in spleen and 
bone marrow. Columns represent mean values ± SD, WT n=3, KO n=4, n.s., not significant,   
* p = 0.015. Wildtype, WT; E2A knockout, KO. 
 
pDC and cDC in bone marrow and spleen derive from the bone marrow CDP 
(Onai et al., 2007b; Naik et al., 2007; Liu et al., 2009). Hence, the presence of 
CDP in bone marrow in vivo and in bone marrow cultures of E2A deficient 
mice was investigated. CDP were found in normal or even increased 
frequencies in vivo and in vitro, indicating that the effect of E2A on pDC 
differentiation is important in a later developmental stage and that CDP 
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develop normally in these mice (Fig. 3.34). Interestingly, both in vivo and in 
vitro amplified CDP express E2A (Fig. 3.34B and C). 
 
 
Figure 3.34. E2A deficient mice give rise to CDP in vivo and in vitro. 
(A and B) CDP in the bone marrow of wild type (A) and E2A deficient (B) mice were analysed 
by flow cytometry as lineage negative Flt3+c-kitintM-CSFR/CD115+ cells. E2A expression 
level was measured as GFP signal intensity from E2A-GFP fusion protein. (C) Progenitors 
were amplified from E2A deficient bone marrow with Flt3L, SCF, hyper-IL-6 and IGF-1 for 7 
days. CDP were analysed by flow cytometry as Flt3+c-kitintM-CSFR/CD115+ cells. E2A 
expression level was measured as GFP signal intensity from E2A-GFP fusion protein. Closed 
histogram, GFP- control; open histogram, GFP signal intensity from E2A-GFP fusion protein. 
Numbers in gates indicate percentage of parent population. Wildtype, WT; knockout, KO. 
 
3.7 Inflammatory DC Development is TGF-β1 Insensitive 
DC differentiation in steady state (recapitulated in Flt3L cultures) is severely 
influenced by TGF-β1, leading to apoptosis of CDP and inhibition of pDC 
development. DC development during inflammation has not been studied in 
greater detail so far. Most probably monocytes instead of CDP serve as DC 
precursors during inflammation (Naik et al., 2006; Shortman and Naik, 2007), 
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and the molecular mechanisms instructing DC development differ from those 
in steady state. To study the influence of TGF-β1 on inflammatory DC 
development, Flt3+CD11b+ DC progenitors were generated with Flt3L, SCF, 
hyper-IL-6, IGF-1, GM-CSF and Dexamethasone (Hieronymus et al., 2005) 
and their differentiation into DC was induced with GM-CSF in the absence or 
presence of TGF-β1. TGF-β1 treatment did not interfere with DC differentiation 
under these conditions, but had a rather beneficial effect on GM-CSF derived 
DC development (Fig. 3.35). TGF-β1 has been reported to positively regulate 
cytokine and growth factor receptor expression, including GM-CSF receptor 
(Jacobsen et al., 1993), and to promote DC differentiation from human CD34+ 
progenitors in vitro (Strobl et al., 1996; Strobl et al., 1997), which would all be 
in agreement with the data presented here. Expression of TGF-β1 target 
genes IRF-8 and Id2 remained unchanged upon TGF-β1 treatment in both DC 
progenitors and DC cultured in the presence of GM-CSF (Fig. 3.36), whereas 
IRF-8 and Id2 were upregulated in Flt3L cultures (Fig. 3.26 and 3.29, Table 
3.4). However, Smad7 expression was upregulated in GM-CSF derived 
progenitors and DC upon TGF-β1 treatment indicating that TGF-β1 signalling 
was induced in the cells (Fig. 3.36). 
 
 
Figure 3.35. GM-CSF induced DC differentiation is not influenced by TGF-β1. 
DC differentiation from Flt3+CD11b+ progenitors was induced with GM-CSF. DC cultures 
were treated with TGF-β1 (3 ng/ml) from differentiation day 2, or left untreated. CD11c, CD24 
and CD11b expression on DC was analysed by flow cytometry at differentiation day 10. 
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Figure 3.36. IRF-8 and Id2 expression is not upregulated by TGF-β1 in 
Flt3+CD11b+/GM-CSF DC progenitors and GM-CSF DC. 
Flt3+CD11b+ progenitors were amplified from bone marrow. DC differentiation was induced 
with GM-CSF. Progenitors (day 7) and DC (day 7) were treated with TGF-β1 for 0, 2, 4, 16 
and 36 hours and analysed for Id2, IRF-8 and Smad7 expression by RT-PCR. Expression of 
HPRT is shown as control. 
 
GM-CSF DC clearly responded to TGF-β1 by upregulating Smad7 expression, 
but the expression of other TGF-β1 target genes was not influenced by 
addition of exogenous TGF-β1. Interestingly, Smad7 expression level in the 
absence of exogenous TGF-β1 was already quite high, although it could be 
further upregulated. LC are the only DC where TGF-β1 signalling has been 
studied into more detail. LC produce high amounts of TGF-β1 (Strobl and 
Knapp, 1999) and both autocrine and paracrine TGF-β1 is required for proper 
LC development in the skin (Kaplan et al., 2007). To investigate whether the 
expression of TGF-β1 target genes is under the control of endogenous, 
autocrine/paracrine TGF-β1 in GM-CSF derived progenitors and DC, the 
production of TGF-β1 in these cells was analysed. Indeed, DC progenitors and 
especially DC cultured in the presence of GM-CSF secreted significant 
amounts of TGF-β1 in the culture medium (Fig. 3.37). In accordance, Smad2/3 
phosphorylation in the absence of exogenous TGF-β1 could be detected, 
indicating to active autocrine/paracrine TGF-β1 signalling (Fig. 3.38C). 
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Figure 3.37. TGF-β1 production by progenitors and DC cultured with GM-CSF. 
Flt3+CD11b+ progenitors were amplified from bone marrow DC differentiation was induced 
with GM-CSF. Culture medium was collected at indicated time points during progenitor/DC 
culture and TGF-β1 concentration was analysed by ELISA. Columns depict TGF-β1 produced 
by the cells and data shown are mean values of triplicates. 
 
If autocrine/paracrine TGF-β1 signalling regulates the expression of IRF-8 and 
Id2 in GM-CSF DC, blocking TGF-β1 would be expected to lead to 
downregulation of their expression. Therefore, recombinant Smad7 
adenovirus was employed to inhibit TGF-β1 signalling. Adenoviral infection in 
DC obtained from transgenic coxsackie adenovirus receptor (CAR) mice 
resulted in very high transduction rates as described before (N. Goncharenko, 
PhD thesis, 2007, Berlin, Germany; Tallone et al., 2001) (Fig. 3.38A). After 
transduction, Smad7 was expressed on high levels (Fig. 3.38B and D) and 
this lead to a complete inhibition of Smad2/3 phosphorylation and, hence, 
TGF-β1 signalling (Fig. 3.38C). However, IRF-8 and Id2 expression remained 
unchanged even when TGF-β1 signalling was completely blocked (Fig. 
3.38D). 
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Figure 3.38. Inhibition of TGF-β1 signalling has no effect on IRF-8 and Id2 expression in 
GM-CSF derived DC. 
Flt3+CD11b+ progenitors were generated from bone marrow of transgenic CAR mice and DC 
differentiation was induced with GM-CSF. DC were infected with recombinant Smad7 
adenovirus or GFP control virus. (A) Transduction efficiency was determined by analysing 
GFP expression in AdGFP infected DC by flow cytometry. (B) Immunoblot analysis of Smad7 
expression in 293T cells and DC infected with AdSmad7 or AdGFP. (C) Phospho-Smad2/3 
and total Smad2 expression in DC after infection with AdSmad7 or AdGFP with and without 
TGF-β1 treatment, or completely untreated. Actin expression is shown as control. (D) Id2, 
IRF-8, Smad and GAPDH expression in DC infected with AdSmad7 or AdGFP or left 
untreated was analysed by RT-PCR. C, negative control.  
 
In conclusion, TGF-β1 signalling does not seem to regulate DC development 
under inflammatory conditions. The expression of TGF-β1 target genes 
identified in human DC and mouse steady state DC, Id2 and IRF-8, seems to 
be regulated in a TGF-β1 independent manner in GM-CSF derived 
inflammatory DC. 
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4 Discussion 
4.1 DC Development from Common DC Progenitors 
An increasingly precise picture of DC development is emerging, including the 
identification of DC-restricted Flt3+c-kitintM-CSFR+ common DC progenitors 
(CDP) (Onai et al., 2007b; Naik et al., 2007; Auffray et al., 2009a; Waskow et 
al., 2008; Liu et al., 2009). At the same time, however, the understanding of 
molecular mechanisms that restrict the developmental potential of progenitors 
and instruct differentiation during the consecutive restriction and differentiation 
steps is lacking behind. This is mainly due to the lack of specific genetic tools 
and in vitro model systems that would allow differentiation stage-specific 
analysis of transcription factors and extrinsic factors involved in the processes. 
Several studies have addressed terminal DC differentiation using conventional 
knockout or transgenic models (reviewed in Zenke and Hieronymus, 2006; Wu 
and Liu, 2007; Shortman and Naik, 2007; Merad and Manz, 2009; Geissmann 
et al., 2010). However, given that the function of any factor will depend on 
other cooperating or antagonistic transcription factors expressed at each 
specific progenitor stage, it has been very difficult to indicate at which 
commitment event the factors exert their functions. 
This study investigated the consecutive development of MPP into CDP and 
their further differentiation into DC subsets, and the impact of TGF-β1 on DC 
differentiation and subset specification from CDP. MPP and CDP were 
obtained in high numbers from bone marrow in a culture system using Flt3L, 
SCF, hyper-IL-6 and IGF-1. CDP were identified as DC-primed progenitors 
giving rise to both cDC and pDC in vitro and in vivo. Accordingly, CDP 
exhibited a DC affiliated gene transcription profile, which is reflected in their 
limited proliferation capacity and DC-directed differentiation potential. The 
amplified in vitro CDP recapitulated the function and surface marker and gene 
expression profiles of in vivo CDP. TGF-β1 accelerated DC differentiation from 
CDP and directed DC subset specification towards cDC by inducing the 
expression of transcription factors that instruct cDC differentiation and/or 
inhibit pDC differentiation. 
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4.1.1 In Vitro Generated CDP 
CDP are very scarce cells in vivo, accounting for about 0.1% of nucleated 
cells in bone marrow. Flt3L is a frequently used cytokine to generate cDC and 
pDC subsets in vitro (Brasel et al., 2000; Brawand et al., 2002; Gilliet et al., 
2002; Naik et al., 2005). Such one-step Flt3L culture systems also generate 
CDP in vitro, but cause an initial selection for Flt3L-responsive cells 
accompanied by massive cell death of unresponsive cells (Naik et al., 2007). 
Importantly, these systems do not amplify CDP into high cell numbers nor do 
they allow the study of the early consecutive steps of hematopoietic cell 
development into DC. Two-step culture systems for progressive and controlled 
development of human and mouse DC from Flt3+ progenitors have been 
described (Hacker et al., 2003; Ju et al., 2003; Ju et al., 2007; Hieronymus et 
al., 2005; Hieronymus et al., 2008). However, these established systems do 
not allow the amplification of CDP or the unrestricted DC differentiation into 
multiple DC subsets in vivo and in vitro. Here I further developed a system that 
allows the amplification of MPP and CDP into high cell numbers from bone 
marrow, and the study of their development into both cDC and pDC. 
The in vitro amplified CDP described here recapitulate the properties of in vivo 
CDP (Onai et al., 2007b; Naik et al., 2007; Waskow et al., 2008; Auffray et al., 
2009a). For example, they exhibit the Flt3+c-kitintM-CSFR+CX3CR1+ surface 
marker profile and the global gene expression profile of in vivo CDP as 
demonstrated here with genome-wide gene expression analysis. In functional 
assays in vivo and in vitro the amplified CDP reproduce the developmentally 
restricted, DC-primed phenotype of in vivo CDP. In addition, the amplified 
CDP readily differentiate into all lymphoid DC subsets in vivo and in vitro, 
showing very rapid differentiation kinetics in vitro in response to all DC-
poietins. 
There are, however, differences between the amplified and in vivo CDP. The 
amplified CDP, for one, express CD11b/Mac-1 (integrin αM). CD11b is 
considered to be a myeloid lineage marker, yet is also expressed on fetal liver 
HSC and short-term reconstituting adult HSC (Morrison and Weissman, 1994; 
Morrison et al., 1995a). Additionally, CD11b expression on CDP described 
here does not seem to reflect a myeloid nature: in colony forming assay and in 
vivo transplantation experiments CDP showed very limited myeloid potential, 
which is in line with published data (Onai et al., 2007b; Naik et al., 2007). The 
in vivo CDP described by Onai et al. (Onai et al., 2007b) and Naik et al. (Naik 
et al., 2007) are CD11b negative, since anti-CD11b antibody is included in the 
lineage depletion protocols for stem/progenitor cell purification. However, CDP 
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from in vitro cultures express CD11b, as demonstrated here and described by 
Naik et al. (Naik et al., 2007). A more notable difference was observed in the 
B cell potential of the in vitro amplified CDP following transplantation in vivo 
and in OP9 co-cultures in vitro. These differences could be related to 
variations in experimental settings used here and in previous reports, such as 
cell numbers used for transplantations and whether or not recipient mice were 
lethally irradiated. It is possible that the engraftment of the in vitro amplified 
and in vivo isolated CDP to bone marrow differs significantly. This could 
influence the B cell potential of the transferred progenitors, since B cell 
development takes place in bone marrow. Indeed, most of the B cell potential 
(approximately 90% in bone marrow compared to less than 5% in spleen) 
from amplified CDP was observed in bone marrow 10 days after 
transplantation. Interestingly, whole-body irradiation has been reported to lead 
to predominant B cell development, instead of myeloid lineages, in bone 
marrow (Tsuboi et al., 2008). Alternatively, the culture system lacks additional 
signals from the bone marrow niche (such as cell-cell and/or cell-matrix 
contacts) that might be required for appropriate CDP commitment. 
Taken together, the in vitro amplified CDP recapitulate the surface marker and 
gene expression profile of the in vivo CDP. They also show similar priming for 
DC differentiation, being still capable of giving rise to multiple DC subsets both 
in vivo and in vitro but having a limited or essentially no potential to generate 
other hematopoietic cells. Hence, the amplified CDP represent a valuable 
system for studying the molecular mechanisms underlying DC lineage 
commitment and DC subset specification at specific differentiation stages. 
 
4.1.2 DC-Priming of CDP 
Cell commitment and differentiation are regulated by extrinsic cues – 
cytokines and growth factors – and intrinsic transcriptional regulators. During 
development of specific hematopoietic lineages the gene expression 
repertoire and the options of stem/progenitor cells become increasingly 
restricted, leading to the establishment of a specific lineage from the choice of 
several. This involves the activation of lineage affiliated genes and repression 
of unrelated genes. Accordingly, during their development from MPP the in 
vitro generated CDP upregulate receptors for all known DC-poietins Flt3L, 
GM-CSF and M-CSF and readily differentiate into all DC subsets in response 
to cognate ligands in vitro. In vivo, CDP generate all lymphoid tissue DC 
subsets after transplantation.  
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Gene expression profiling revealed that DC specific transcription profiles are 
activated from MPP to CDP and further to the DC subsets. Consistent with 
their capacity to generate both cDC and pDC, CDP express pan-DC genes as 
well as genes specific for either DC subset. Interestingly, genes important for 
DC function, such as pattern recognition (TLR2 and TLR7), antigen 
processing (cathepsin S) and MHC class II presentation (legumain) (Akira et 
al., 2001; Nakagawa et al., 1999; Manoury et al., 1998), are already 
upregulated from MPP to CDP. Thus, CDP harbour the molecular machinery 
that upon proper stimuli enables full DC differentiation and DC subset 
specification. 
CDP downregulate c-kit and IGF-1 receptor and upregulate Flt3 and gp130 
receptor when differentiating from MPP (Table 3.2 and data not shown). The 
c-kit ligand SCF is an important cytokine for regulating HSC numbers and 
function (Lyman and Jacobsen, 1998). Flt3L acts on the common lymphoid 
progenitor (CLP) pool and early lymphopoiesis (Sitnicka et al., 2002). 
Upregulation of Flt3 expression in bone marrow stem cells is accompanied by 
loss of long-term self-renewal capacity (Adolfsson et al., 2001). Additionally, 
Flt3L is acknowledged as a major DC poietin and DC development is strongly 
dependent on Flt3/STAT3 signaling (Laouar et al., 2003; Onai et al., 2006). IL-
6/IL-6R signaling via gp130 can further synergize with Flt3L/STAT3 to induce 
generation of DC-primed progenitors (Cohen et al., 2008). Consequently, the 
four-factor cocktail (Flt3L, SCF, hyper-IL-6, IGF-1) (i) readily induces self-
renewal of MPP and their progression into CDP and (ii) has no self-renewal 
activity on CDP but rather induces their differentiation into DC. In line with the 
loss of self-renewal capacity and multilineage potential, CDP differentiation 
from MPP is accompanied by downregulation of stem/progenitor cell 
associated gene expression. Thus, in parallel to acquiring a DC-primed 
receptor and transcription factor repertoire, CDP downregulate receptors and 
transcription factors important for stem cell proliferation and self-renewal. 
In conclusion, bone marrow cultures with Flt3L, SCF, hyper-IL-6 and IGF-1 
recapitulate the consecutive development of MPP to CDP and allow their 
further development into specific DC subsets. So far, many studies have 
addressed the question of terminal DC development and DC function. The 
system described here now enables detailed studies on the molecular 
mechanisms underlying early DC development from hematopoietic 
stem/progenitor cells. The identification of the DC-primed transcription profile 
in CDP represents the first step in this direction and opens the perspective for 
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the identification of specific instructive factors for CDP commitment and DC 
subset specification. 
 
4.2 Impact of TGF-β1 on DC Development 
4.2.1 TGF-β1 Accelerates DC Differentiation and Directs DC Subset 
Specification Towards cDC 
The crucial role of TGF-β1 in LC development is well established (Borkowski 
et al., 1996; Strobl et al., 1996; Strobl et al., 1997), whereas the effect of TGF-
β1 on the development of other DC subsets has remained elusive. Thus, I 
employed the in vitro system described here to study the impact of TGF-β1 on 
CDP differentiation and subset specification. Genome-wide gene expression 
analysis demonstrated that TGF-β1 pushed the CDP transcription profile 
towards DC within 24 h. This included the upregulation of so-called pan-DC 
genes, such as Flt3, which is crucial for DC development and directs the DC 
priming of CDP, as discussed above. In addition, several genes related to DC 
function, like antigen processing and presentation, were already induced after 
24 h TGF-β1 treatment. Concomitantly, the expression of genes involved in 
cell proliferation was downregulated. This all indicates that TGF-β1 
accelerates DC differentiation from CDP. In line with these observations, the 
expression of TGF-β1 target genes identified here and previously, such as Id2 
and IRF-8, is upregulated during DC differentiation and further enhanced upon 
addition of exogenous TGF-β1 (Hacker et al., 2003; Ju et al., 2007). 
In addition, TGF-β1 directed DC subset specification from CDP towards cDC 
at the expense of pDC development. TGF-β1 treated CDP acquired a cDC 
affiliated transcription factor repertoire with the induction of cDC differentiation 
instructing transcriptional regulators, including IRF-4 and several members of 
the NF-κB family (Gabriele and Ozato, 2007; Burkly et al., 1995; Wu et al., 
1998). TGF-β1 also induced transcription factors that inhibit pDC 
differentiation, such as Id2 and IRF-1 (Hacker et al., 2003; Gabriele et al., 
2006). These results are very much in line with the observation that ectopic 
Id2 expression compromises pDC development (Spits et al., 2000) and that 
Id2 deficient mice have increased pDC frequencies (Hacker et al., 2003). Id2 
is a HLH transcription factor that lacks the adjacent basic region required for 
DNA binding and thereby antagonizes activating HLH factors, like E2-2/Tcf4 
and E2A, in a DNA-independent manner (Fig. 4.1) (Kee, 2009). E2-2/Tcf4 is a 
HLH factor essential for pDC development, as demonstrated by gene 
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knockout studies (Cisse et al., 2008; Nagasawa et al., 2008). Conversely, 
overexpression of activating HLH factors, such as HEB and E2A, were 
reported to promote pDC development (Schotte et al., 2004). 
Bhlhe40/Stra13/Dec1 represents another HLH factor that is induced in CDP by 
TGF-β1. Bhlhe40/Stra13 acts as transcriptional repressor while binding to E-
box DNA elements and thus antagonizes other HLH factors in a DNA-
dependent manner (Fig. 4.1) (St-Pierre et al., 2002). Thus, it is tempting to 
speculate that Bhlhe40/Stra13 might be yet another transcription factor that 
represses pDC development. The involvement of other factors than Id2 in the 
inhibition of pDC development upon TGF-β1 treatment is strongly supported 
by the fact that deletion of Id2 alone was not sufficient to revert the inhibitory 
activity of TGF-β1 on pDC development. 
 
Figure 4.1. TGF-β1 induced genes instruct cDC differentiation or inhibit pDC 
differentiation. 
TGF-β1 induces cDC differentiation promoting genes, such as IRF-4 and the NF-kB family 
members in CDP. Concomitantly, pDC differentiation is inhibited by upregulation of repressive 
HLH transcription factors, such as Id2 and Stra13, that repress transcription by activating HLH 
factors, like E2-2 or E2A, in a DNA-dependent or DNA-independent manner. Helix-loop-helix 
factor, HLH. 
 
In summary, for the first time TGF-β1 was identified as a determining factor 
that acts on the bifurcation point of cDC versus pDC development and directs 
DC subset specification from CDP. Interestingly, TGF-β1 has most recently 
been implicated in regulating HSC subpopulations, having a selective impact 
on myeloid-biased HSC at the expense of lymphoid-biased HSC both in vivo 
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and in vitro (Challen et al., 2010). Hence, TGF-β1 signalling represents a 
potential mechanism for differential regulation of hematopoietic cells, whether 
on early HSC level or in DC subset specification. TGF-β1 signals via a 
ubiquitously expressed pathway and virtually every cell has the potential of 
producing TGF-β1 and responding to it (Massague, 2000; Larsson and 
Karlsson, 2005; Taylor, 2009). Therefore, TGF-β1 signalling is precisely 
regulated by mechanisms that convert latent TGF-β1 to its active form 
(Massague and Chen, 2000; Taylor, 2009). In bone marrow, TGF-β1 is widely 
expressed in its latent form by the niche cells, including osteoblasts and other 
stromal cells, and also by HSC (Larsson and Karlsson, 2005). However, HSC 
themselves seem to lack the capacity to activate latent TGF-β1 (Yamazaki et 
al., 2009). Also DC have been described to produce TGF-β1 (Strobl and 
Knapp, 1999; Kaplan et al., 2007), as also shown here for GM-CSF derived 
DC, but only few studies have addressed the activation of latent TGF-β1 in DC 
or immune cells in general. There is evidence for a role of DC in TGF-β1 
activation from mice that lack the  αVβ8 integrin specifically on their DC 
(Travis et al., 2007; Yang et al., 2007). It remains unclear whether the same 
mechanisms work in bone marrow during DC development from CDP. It is 
tempting to speculate on a context-dependent (e.g. bone marrow niche-
dependent) activation of TGF-β1 that directs DC subset differentiation towards 
cDC. 
Of notice, TGF-β1 has also been described to inhibit pro-B cell growth and 
survival (Kee et al., 2001). The negative activity of TGF-β1 on lymphoid cells 
and pDC, as described here, raises the intriguing question of the relation of 
DC subsets to myeloid and lymphoid lineages. Although all DC subsets can 
derive from Flt3+ expressing lymphoid and myeloid progenitors, DC are 
generally regarded as myeloid cells. Yet, pDC exhibit several features 
characteristic for lymphoid lineage cells: (i) pDC, like lymphoid cells, show 
immunoglobulin heavy chain D-J gene rearrangements (Corcoran et al., 
2003), (ii) pDC express the pre-T cell receptor α chain transcripts (Grouard et 
al., 1997; Bendriss-Vermare et al., 2001), (iii) pDC employ a different promoter 
region for expression of CIITA, the “master regulator” of MHC class II genes 
(LeibundGut-Landmann et al., 2004), relying strictly on the B cell promoter that 
differs from the promoter used by other DC and macrophages, (iv) pDC 
development, similar to B and T cell development and unlike myeloid cell and 
cDC development, is sensitive to Id2 and Id3 expression (Spits et al., 2000). 
Hence, pDC resemble lymphoid cells, especially B cells, in various aspects of 
their development and function. 
DISCUSSION 85 
 
4.2.2 E2A in DC Differentiation 
Given (i) the resemblance of pDC with B cells and (ii) their sensitivity to 
ectopic Id2 and Id3 expression (Spits et al., 2000) and (iii) the concurrent 
positive impact of HLH factor overexpression on pDC development (Schotte et 
al., 2004), I speculated that one or several of the activating HLH proteins 
might be required for pDC development. Recently, E2-2 (encoded by Tcf4) 
was described as a pDC specific HLH factor (Cisse et al., 2008; Esashi and 
Liu, 2008). Here, I studied the impact of E2A, another E-box HLH protein, on 
pDC development. E2A, encoding two alternative proteins E12 and E47, is 
well known for its crucial role in B cell development (Kee, 2009). Employing 
the conditional E2A knockout model, I show that E2A deficient bone marrow 
cells are completely blocked in pDC development in vitro. In addition, pDC 
frequencies in bone marrow in vivo were decreased in E2A deficient mice. 
pDC frequencies in spleen, however, and cDC development in general were 
not affected in the absence E2A. pDC have been described to consist of two 
subpopulations in bone marrow in vivo (Pelayo et al., 2005). By employing 
knock-in mice that express GFP under the recombination activating gene 1 
(RAG1) promoter, Pelayo et al. (Pelayo et al., 2005) could subdivide pDC into 
GFP+ and GFP- fractions. Interestingly, only the GFP+ pDC exhibited the 
lymphoid markers, such as immunoglobulin gene rearrangements and 
expression of B-lineage related genes. It is yet unclear whether pDC 
development recapitulated in the in vitro Flt3L cultures also reproduces this 
subdivision into RAG1/GFP+ and RAG1/GFP- fractions or whether only one of 
the potential pDC developmental pathways is used under these culture 
conditions. This might also explain the difference in the extent of impaired 
pDC development observed in E2A deficient mice in vitro versus in vivo. It is 
also reasonable to assume that compensating mechanisms can take place in 
vivo that lack in the in vitro culture models. 
 
4.2.3 TGF-β1 in DC Development During Steady State and Inflammation 
DC develop from different progenitors and depend on the action of different 
cytokines in steady state and inflammatory conditions (discussed in Chapter 
1.6) (Shortman and Naik, 2007; Geissmann et al., 2010). Therefore, the 
impact of TGF-β1 on DC development might be different under steady state 
conditions, recapitulated in the CDP and Flt3L-driven DC cultures, and 
inflammatory conditions. To test this, DC progenitors were generated with 
Flt3L, SCF, hyper-IL-6, IGF-1, GM-CSF and Dexamethasone (Hieronymus et 
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al., 2005) and their differentiation into DC was induced with GM-CSF, which 
recapitulates inflammatory DC differentiation (Naik et al., 2005; Naik et al., 
2006; Shortman and Naik, 2007). GM-CSF DC differentiation was normal or 
even enhanced under TGF-β1 treatment. Indeed, TGF-β1 has been described 
to have a DC differentiation promoting activity in vitro when cytokine cocktails 
containing GM-CSF were used (Strobl et al., 1996; Strobl et al., 1997). In 
accordance, TGF-β1 upregulates GM-CSF receptor expression in bone 
marrow progenitors (Jacobsen et al., 1993). Progenitors and DC cultured with 
GM-CSF showed no regulation of Id2 or IRF-8 expression upon TGF-β1 
treatment, which is in contrast to steady state DC progenitors (CDP) and DC. 
Interestingly, Id2 was expressed in high levels in untreated GM-CSF 
progenitors, whereas IRF-8 expression was not detected in these cells. This 
could relate to the impaired potential of GM-CSF progenitors to generate pDC 
in vitro, considering the crucial roles of Id2 and IRF-8 in pDC development 
(Spits et al., 2000; Schiavoni et al., 2002; Hacker et al., 2003). In fact, GM-
CSF signalling via STAT5 inhibits pDC development by suppressing IRF-8 
expression (Esashi et al., 2008). Both Id2 and IRF-8 were expressed in GM-
CSF derived DC, which relates to the important role of IRF-8 in DC function 
(Schiavoni et al., 2004; Mattei et al., 2006; Tailor et al., 2007). Importantly, 
progenitors and DC cultured with GM-CSF were able to respond to exogenous 
TGF-β1 and GM-CSF derived DC also produced high levels of TGF-β1. The 
expression of some typical TGF-β1 target genes, like Id2 and IRF-8, seems 
not to be under TGF-β1 control in these cells, as demonstrated by addition of 
exogenous TGF-β1 or complete blocking of TGF-β1 signalling. 
In conclusion, TGF-β1 acts as a determining factor on the bifurcation point of 
cDC versus pDC development in steady state, but does not seem to regulate 
DC differentiation under inflammatory conditions. This would be in line with the 
assumption that steady state and inflammatory DC development exploit 
separate pathways in terms of progenitor cells and molecular requirements for 
development. TGF-β1 target genes that are crucial for steady state DC 
development and subset specification seem to be dispensable in GM-CSF 
induced DC development, as GM-CSF DC develop normally from Id2 and IRF-
8 deficient mice (data not shown). The role of TGF-β1 in inflammatory 
conditions might be more to dampen the function of innate immune cells, 
including inflammatory DC (Sanjabi et al., 2009). This is supported by studies 
showing that GM-CSF derived DC cultured in the presence of TGF-β1 develop 
normally, but acquire a tolerogenic phenotype with reduced capacity for 
antigen presentation and T cell activation (Kobie et al., 2003; Mou et al., 2004; 
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Ronger-Savle et al., 2005; Farquhar et al., 2010). Accordingly, TGF-β1 
represents one mechanism utilised by tumour cells to escape DC-induced 
immune reactions (Kobie et al., 2003; Weber et al., 2005). 
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6 Appendix 
6.1 Abbreviations 
ALK  activin receptor-like kinase 
αMEM minimum essential medium, alpha 
APC  antigen-presenting cell 
APC  allophycocyanin 
APS  ammonium per-sulfate 
BCR  B cell receptor 
BMP  bone morphogenic protein 
CAR  coxsackie adenovirus receptor 
CD  cluster of differentiation 
cDC  conventional DC 
cDNA  complementary DNA 
CDP  common DC progenitor 
CFSE  carboxyfluorescein diacetate succinimidyl ester 
CLP  common lymphoid progenitor 
CLR  C-type lectin receptor 
CMP  common myeloid progenitor 
Co-Smad common-partner Smad 
cRNA  complementary RNA 
DC  dendritic cell 
Dex  dexamethasone 
DMEM Dulbeccoʼs modified Eagle medium  
DNA  deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
FACS  fluorescence activated cell sorter 
FCS  fetal calf serum 
FITC  Fluorescein isothiocyanate 
Flt3  FMS-like tyrosine kinase 3 
Flt3L  Flt3 ligand 
GDF  growth and differentiation factor 
GFP  green fluorescent protein 
GM-CSF granulocyte/macrophage colony stimulating factor 
GMP  granulocyte/macrophage progenitor 
GO  gene ontology 
HBSS  Hankʼs buffered salt solution 
HCl  hydrochloric acid 
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HLH  helix-loop-helix 
HSC  hematopoietic stem cell 
ICSBP interferon consensus sequence binding protein 
Id  inhibitor of differentiation/DNA binding 
Ig  immunoglobulin 
IGF  insulin-like growth factor 
IL  interleukin 
I-Smad inhibitory Smad 
IFN  interferon 
iNOS  inducible nitric oxide synthase 
IRF  interferon regulatory factor 
kDa  kilo Dalton 
KO  knockout 
LAP  latency-associated protein 
LC  Langerhans cell 
MACS  magnetic activated cell sorting 
MAPK  mitogen-activated protein kinase 
M-CSF macrophage colony-stimulating factor 
M-CSFR macrophage colony-stimulating factor receptor 
MDP  macrophage/DC progenitor 
MEP  megakaryocyte/erythrocyte progenitor 
MkE  megakaryocyte-erythroid 
MHC  major histocompatibility complex 
MPP  multipotent progenitor 
nd  not determined 
NF  nuclear factor 
NK  natural killer cell 
NKT  natural killer T cell 
PAMP  pathogen-associated molecular pattern 
PBS  phosphate buffered saline 
PCA  principal component analysis 
PE  R-Phycoerythrin 
PI  propidium iodide 
pDC  plasmacytoid DC 
PVDF  Polyvinylidenfluorid 
RAG  recombination activating gene 
RNA  ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
R-Smad receptor Smad 
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RT-PCR reverse transcriptase polymerase chain reaction 
SCF  stem cell factor 
SDS  sodium dodecyl phosphate 
SDS-PAGE SDS-polyacrylamid-gelelectrophorese 
STAT  signal transducer and activator of transcription 
TBS  Tris based saline 
TCR  T cell receptor 
TEMED N,N,Nʼ,Nʼ-Tetramethylethylenediamine 
TGF-β  transforming growth factor-β 
Th  T helper 
TipDC  TNFα, iNOS producing DC 
TNFα  tumour necrosis factor  α 
TLR  Toll like receptor 
TPO  thrombopoietin 
Treg  regulatory T cell 
U  unit 
UV  ultraviolet 
WT  wild type 
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